17th NSV2018 Verona ITALY

June 17-22, 2018

General Information

MEETING ORGANIZERS

Dominique Garcin: University of Geneva, Switzerland Grazia Cusi: University of Siena, Siena, Italy Wendy Barclay: Imperial College, London, UK Paul Duprex: Boston University, Boston, USA Sean Whelan: Harvard Medical School, Boston, USA

The organizers gratefully acknowledge David Zenaty and Keith Ketterer, Harvard Medical School for administrative and website support USEFUL NUMBERS

Administrative Secretariat: Local Secretariat: MCI Geneva Iantra 9, rue Pré-Bouvier Piazza Donatori di Sangue 5 1242 Satigny / Geneva 37124 Verona Switzerland Italy Onsite Phone: +41 765714224 Email: [email protected]

Emergency: 118 Local Police: 112 / 113 Ambulance: 118 History of NSV

The first meeting, entitled “The biology of large RNA viruses” was organized by Richard D. Barry and Brian W. J. Mahy in 1969, Cambridge England. A symposium volume was published following this congress and includes presentations on negative-strand RNA viruses and retroviruses. The meeting predated the discovery of reverse transcriptase and the recognition that the negative-strand RNA viruses contain an RNA polymerase within the virion.

This is the premier meeting in the field of negative strand RNA viruses. The conference is limited in size to approximately 400 participants, with presentations that cover all aspects of the fundamental biology of negative strand RNA viruses. This is the 17th meeting and we continue in the spirit of previous conferences and there will be no invited speakers or concurrent sessions.

NSV 1969: Pembroke College, Cambridge, UK NSV 1973: King’s College, Cambridge, UK NSV 1977: King’s College, Cambridge, UK NSV 1980: St. Thomas, Virgin Islands, USA NSV 1982: Hilton Head, NC, USA NSV 1985: Robinson College, Cambridge, UK NSV 1988: Palais des Congrès, Dinard, France NSV 1991: Hibernian Hall, Charleston, SC, USA NSV 1994: Hotel Estoril Sol, Estoril, Portugal NSV 1997: Trinity College, Dublin, Ireland NSV 2000: Palais Montcalm, Québec City, Canada NSV 2003: Palazzo dei Congressi, Pisa, Italy NSV 2006: Hospederia de Fonseca, Salamanca, Spain NSV 2010: Concertgebouw, Bruges, Belgium NSV 2013: Palacio de Congresos, Granada, Spain NSV 2015: Università di Siena, Siena, Italy NSV 2018: Gran Guardia Palace, Verona, Italy

The scientific program is complemented by a vibrant social program designed to foster interactions among all of the attendees, welcome newcomers to the field, strengthen our community and provide life-long memories. Future of NSV

The organizing committee would like to encourage you to visit Poster P000 so that you can have input on the future of NSV. This poster will remain up throughout the meeting and we ask that you visit the poster and talk to the organizers. Among the topics we seek feedback on are:

• Formation of a non-profit organization whose sole objective is the organization of the Negative Strand Virus meeting • Membership of the non-profit organization • Culture of the meeting • Ensuring access to all members of the community

Image courtesy of Rebekah Dumm and Nick Heaton, Duke University, USA Verona

In fair Verona, where we lay our scene …

Roman theater duomo

piazza Erbe

Juliet’s balcony

arena piazza Bra

Gran Guardia Social Program

WELCOME RECEPTION

The welcome reception will take place on the terrace of the Gran Guardia Palace from 19:00-22:00 on Sunday, June 17. Come and see the view of the Arena, meet old and new friends and enjoy some Italian hospitality.

WALKING TOUR OF VERONA

The historic city of Verona was founded in the 1st Century BC. Verona has preserved a remarkable number of monuments from antiquity, the medieval and Renaissance periods, and represents an outstanding example of a military stronghold. So splendid is the city that its reputation alone inspired Shakespeare to set two plays here. We will learn about the city’s past as we wander the charming streets on Monday, June 18. Social Program

DINNER BY THE LAKE

A trip to this region would be incomplete without visiting Lake Garda – the largest lake in Italy. Take time to walk around the picturesque town of Lazise and then have an aperitif followed by a buffet at the Dogana Veneta. Buses leave from the Gran Guardia at 18:30 on Tuesday, June 19.

GALA DINNER

The Gala Dinner has been a highlight of the NSV social program since its inception. Join us at beautiful Villa Arvedi – built in the 17th Century – and frescoed by the French painter Ludovico Dorigny. Buses leave from the Gran Guardia at 18:45 on Thursday, June 21. Week at a glance

PROGRAM

SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY 9 BREAKING EXPRESSING BUILDING DAMAGING & & & & EMERGING 10 ENTERING MULTIPLYING ESCAPING SPREADING & EVOLVING COFFEE & POSTERS 11 COFFEE

SUPPRESSING FIGHTING EMERGING BREAKING & BUILDING & 12 & & CONQUERING & RESPONDING EVOLVING ENTERING ESCAPING

13 LUNCH & POSTERS LUNCH

14 SUPPRESSING FIGHTING & & EXPRESSING DAMAGING CONQUERING RESPONDING 15 & & MULTIPLYING SPREADING

COFFEE & POSTERS 16 SUPPRESSING FIGHTING & & REGISTRATION 17 EXPRESSING CONQUERING DAMAGING RESPONDING & & MULTIPLYING SPREADING 18

19 WALKING WELCOME TOUR LAKE GARDA 20 RECEPTION DOGANA 21 GALA DINNER GRAN FREE EVENING VENETA FREE EVENING VILLA ARVEDI 22 GUARDIA

23

00 Sunday June 17

14:00-18:30 Registration: Gran Guardia Piazza Bra, 1 37121 Verona

Poster Session One: P000, P230, P001-P123 Monday, June 18 and Tuesday June 19 Poster dismantling Tuesday, June 19, at the end of the session Poster Session Two: P000, P230, P124-P249 Wednesday, June 20 and Thursday June 21 Poster dismantling Thursday, June 21, at the end of the session

19:00-22:00 Welcome Reception at Gran Guardia Session One Monday June 18

BREAKING AND ENTERING

08:50-09:00 WELCOME TO NSV2018

09:00-09:10 Anne MOSCONA and Kartik CHANDRAN Chairpersons' remarks

1 09:10-09:30 Silke STERTZ HUMAN LEUCOCYTE ANTIGEN DR (HLA-DR) HOMOLOGS ARE CROSS- SPECIES ENTRY RECEPTORS FOR BAT INFLUENZA VIRUSES. UNIVERSITY OF ZURICH, Zurich, Switzerland 2 09:30-09:50 Roberto CATTANEO NECTINS TRANSFER CYTOPLASM BETWEEN CELLS AND CAN SPREAD MEASLES VIRUS TO NEURONS MAYO CLINIC, Rochester, United States 3 09:50-10:00 Donald BENTON STRUCTURE OF FULL-LENGTH INFLUENZA HAEMAGGLUTININ THE FRANCIS CRICK INSTITUTE, London, United Kingdom 4 10:00-10:10 Aurelie ALBERTINI STRUCTURAL BASIS OF LOW-DENSITY LIPOPROTEIN RECEPTOR RECOGNITION BY VSV GLYCOPROTEIN CNRS, GIF SUR YVETTE, France 5 10:10-10:20 Eva MITTLER DELINEATING INTERACTION OF FILOVIRAL GP WITH ITS ENDOSOMAL RECEPTOR NPC1 BY IN SITU PROXIMITY LIGATION ALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States 6 10:20-10:30 Rohit JANGRA HOST FACTOR REQUIRED FOR IN VIVO PATHOGENICITY OF NEW WORLD HANTAVIRUSES ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

COFFEE BREAK WITH POSTERS 10:30-11:30 MondayBREAKING AND ENTERINGJune 18

7 11:30-11:50 Rebecca DUTCH ANCHORING THE SPRING: THE ROLE OF TRANSMEMBRANE DOMAIN INTERACTIONS IN VIRAL FUSION PROTEIN FUNCTION UNIVERSITY OF KENTUCKY, Lexington, United States 8 11:50-12:10 Hector AGUILAR-CARRENO UNCOVERING A NEW PARAMYXOVIRAL ATTACHMENT GLYCOPROTEIN ROLE BEYOND FUSION TRIGGERING CORNELL UNIVERSITY, Ithaca, United States 9 12:10-12:30 Nicole TISCHLER HANTAVIRUS GC HOMOMERIC DIMER AND TRIMER CONTACTS DIRECT SPIKE DISSOCIATION AND MEMBRANE FUSION FUNDACIÓN CIENCIA PARA LA VIDA, Santiago, Chile 10 12:30-12:40 Ilona RISSANEN ANTIGENIC ARRANGEMENT OF THE DYNAMIC HANTAVIRAL SURFACE UNIVERSITY OF HELSINKI, Helsinki, Finland 11 12:40-12:50 Chiara FEDELI RECEPTOR TYROSINE KINASES ARE PROMISING TARGETS IN LASSA VIRUS ANTIVIRAL THERAPY CHUV, Lausanne, Switzerland

LUNCH 12:50-14:20

Session Two EXPRESSING AND MULTIPLYING

14:20-14:30 Ervin FODOR, Ben HALE and Rachel FEARNS Chairpersons' remarks

12 14:30-14:50 Juan REGUERA STRUCTURE AND FUNCTION OF PHENUIVIRIDAE CAP-SNATCHING ENDONUCLEASES INSERM, Marseille, France 13 14:50-15:10 Sean WHELAN MECHANISM OF POLYMERASE REGULATION BY A 5’ HOOK LIKE STRUCTURE IN THE GENOMIC RNA OF MACHUPO VIRUS. HARVARD MEDICAL SCHOOL, Boston, United States 14 15:10-15:20 Haitan FAN STRUCTURAL INSIGHTS INTO THE MECHANISMS OF INFLUENZA A VIRUS RNA REPLICATION UNIVERSITY OF OXFORD, Oxford, United Kingdom 15 15:20-15:30 Akiko MAKINO TRANSLATIONAL REGULATION OF BORNA DISEASE VIRUS KYOTO UNIVERSITY, Kyoto, Japan 16 15:30-15:50 Jianrong LI VIRAL N6-METHYLADENOSINE PROMOTES REPLICATION AND GENE EXPRESSION OF PNEUMOVIRUSES THE OHIO STATE UNIVERSITY, Columbus, United States

COFFEE BREAK AND POSTERS 15:50-16:50 EXPRESSING AND MULTIPLYING

17 16:50-17:10 Christopher BASLER PROTEOMIC ANALYSIS IDENTIFIES HUMAN E3 UBIQUITIN LIGASE RBBP6 AS A NEGATIVE REGULATOR OF EBOLA VIRUS INFECTION GEORGIA STATE UNIVERSITY, Atlanta, United States 18 17:10-17:20 Simone BACH ADVANCED ANALYSES ON THE ROLE OF VP30 AND RNA STRUCTURES IN EBOLA VIRUS TRANSCRIPTION PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany 19 17:20-17:40 Andrew MEHLE REPURPOSING CANONICAL ANTIVIRAL RESPONSES TO PROMOTE TRANSLATION OF INFLUENZA VIRUS MESSENGER RNAs UNIVERSITY OF WISCONSIN MADISON, Madison, United States 20 17:40-17:50 Jason LONG BINDING TO ANP32 IS REQUIRED BUT NOT SUFFICIENT FOR INFLUENZA A VIRUS POLYMERASE ACTIVITY IMPERIAL COLLEGE LONDON, London, United Kingdom 21 17:50-18:10 Anice LOWEN INCOMPLETE GENOMES OF INFLUENZA A VIRUS DRIVE ABUNDANT REASSORTMENT Emory University, Atlanta, United States

GUIDED TOURS OF VERONA 18:30 #NSV2018

WALKING TOUR OF VERONA

Guided tours leave from the front of Gran Guardia from 18:30-19:00

Tonight we explore the city and a highlight will be the famous Juliet’s balcony.

• Band-Aids and a Sharpie are in your bag!

• suggested activity see photograph below

• meet someone new and share the results broadly with the #NSV2018 community on social media or email them to [email protected].

• If you don’t tweet what better time to start … enjoy! Tuesday June 19

EXPRESSING AND MULTIPLYING

22 09:00-09:20 Rachel FEARNS DIFFERENCES BETWEEN TRANSCRIPTION AND REPLICATION INITIATION MECHANISMS OF THE PNEUMO- AND PARAMYXOVIRIDAE BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States 23 09:20-09:40 Richard RANDALL NEXT GENERATION SEQUENCING REVEALS NOVEL ASPECTS OF PARAMYXOVIRUS TRANSCRIPTION AND REPLICATION AND THE SWITCH BETWEEN ACUTE AND PERSISTENT INFECTIONS. UNIVERSITY OF ST ANDREWS, St Andrews, United Kingdom 24 09:40-09:50 Louis-Marie BLOYET STRUCTURE GUIDED TUNING OF VESICULAR STOMATITIS VIRUS RNA DEPENDENT RNA POLYMERASE FIDELITY HARVARD MEDICAL SCHOOL, Boston, United States 25 09:50-10:00 Ryan DONOHUE TO V, OR NOT TO V? CYCLIC SELECTION OF GENOMIC QUASISPECIES WITH ALTERNATIVE CODING CAPACITIES IN DUAL-TROPIC MEASLES VIRUS MAYO CLINIC, Rochester, United States 26 10:00-10:20 Chris BROOKE INFLUENZA A VIRUS GENOMIC HETEROGENEITY REGULATES SUPERINFECTION POTENTIAL AND THE CELLULAR RESPONSE TO INFECTION UNIVERSITY OF ILLINOIS, Urbana, United States

COFFEE AND POSTERS 10:20-11:10

Session Three SUPPRESSING AND CONQUERING

11:10-11:20: Ryan LANGLOIS, Friedemann WEBER and Gaya AMARASINGHE Chairpersons' remarks

27 11:20-11:40 Karl-Klaus CONZELMANN NUCLEAR IMPORT OF THE RABIES VIRUS P PROTEIN IS REQUIRED FOR INHIBITION OF RIG-I-LIKE RECEPTOR-MEDIATED TYPE I INTERFERON INDUCTION LMU MUNICH, München, Germany 28 11:40-12:00 Stephane BIACCHESI NOVIRHABDOVIRUS NV PROTEINS ACT AS ANTAGONISTS OF THE HOST ANTIVIRAL DEFENSE INRA, Jouy en Josas, France 29 12:00-12:20 Daisy LEUNG MECHANISMS OF IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINS WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States 30 12:20-12:30 Raquel MUÑOZ-MORENO A BARCODED LIBRARY UNVEILS NS1-DRIVEN INFLUENZA VIRUS TROPISM ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States 31 12:30-12:40 Cornelius ROHDE MARBURG VIRUS PROTEIN VP30 REGULATES THE IRE1/XBP1-DEPENDENT UNFOLDED PROTEIN RESPONSE TO ENSURE EFFICIENT VIRAL REPLICATION Institute of Virology, Philipps-University Marburg, Marburg, Germany

LUNCH AND POSTERS 12:40-13:50 SUPPRESSING AND CONQUERING

32 13:50-14:10 Alexander BUKREYEV SUBVERSION OF LYMPHOCYTE RESPONSE AND MODULATION OF GENE EXPRESSION AND SIGNALING BY EBOLA VIRUS University of Texas Medical Branch at Galveston, Galveston, United States 33 14:10-14:30 Amelia NIETO EPIGENETIC CONTROL OF INFLUENZA VIRUS MEDIATED BY H3K79 HISTONE METHYLATION: ROLE IN INTERFERON-INDUCED ANTIVIRAL RESPONSE CENTRO NACIONAL DE BIOTECNOLOGIA-CSIC, Madrid, Spain 34 14:30-14:50 Marta GAGLIA THE INFLUENZA A VIRUS HOST SHUTOFF RNASE PA-X USURPS HOST mRNA PROCESSING MECHANISMS TUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, United States 35 14:50-15:00 Linda BRUNOTTE TRIM28/KAP1 IS A PKR-CONTROLLED NEGATIVE REGULATOR OF THE INNATE IMMUNE RESPONSE TO HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUSES UNIVERSITY OF MUENSTER, Muenster, Germany 36 15:00-15:10 Béryl MAZEL-SANCHEZ H5N1 INFLUENZA A VIRUS PB1-F2 RELIEVES HAX-1-MEDIATED RESTRICTION OF AVIAN VIRUS POLYMERASE PA IN HUMAN LUNG CELLS UNIVERSITY OF GENEVA, Geneva, Switzerland

COFFEE AND POSTER SESSION 15:10-16:00 SUPPRESSING AND CONQUERING

37 16:00-16:20 Caroline GOUJON IDENTIFICATION OF A NEW INTERFERON-INDUCIBLE PROTEIN INHIBITING ENDOSOME MEDIATED VIRAL ENTRY THROUGH REGULATION OF THE VACUOLAR H+-ATPASE INSTITUT DE RECHERCHE EN INFECTIOLOGIE DE MONTPELLIER (IRIM), CNRS/MONTPELLIER UNIVERSITY, Montpellier, France 38 16:20-16:40 Patrick READING DEFINING HOST RESTRICTION FACTORS THAT MODULATE RESPIRATORY VIRUS ENTRY AND EXIT FROM INFECTED CELLS. PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia 39 16:40-16:50 Rui GALAO TRIM25 TARGETS EBOLA VIRUS RIBONUCLEOPROTEIN TO SENSITIZE IT TO ZAP-MEDIATED RESTRICTION KING'S COLLEGE LONDON, London, United Kingdom 40 16:50-17:00 Florine SCHOLTE INHIBITION OF THE CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS- ENCODED DEUBIQUITINASE BLOCKS VIRAL REPLICATION CDC, Atlanta, United States 41 17:00-17:10 Carles SOLÀ RIERA HANTAAN VIRUS DOWNREGULATES CELL SURFACE EXPRESSION OF DEATH RECEPTOR 5 VIA THE 26S PROTEASOME PATHWAY AND INHIBITS TRAIL-MEDIATED INDUCTION OF APOPTOSIS KAROLINSKA INSTITUTET, Stockholm, Sweden 42 17:10-17:20 Elizabeth FAY REPLICATION HETEROGENEITY DRIVES DISTINCT CELLULAR RESPONSES TO INFLUENZA A INFECTION IN VIVO UNIVERSITY OF MINNESOTA, Minneapolis, United States

REMOVE SESSION ONE POSTERS UNREMOVED POSTERS AFTER 17.45 WILL BE DISCARDED!

SOCIAL PROGRAM VISIT TO DOGANA VENETA

BUSES DEPART GRAN GUARDIA 18:30-19:00

RETURN FROM 22:00 Lake Garda

DOGANA VENETA

Buses leave from the front of Gran Guardia at 18:30-19:00

Tonight we visit the lakeside village of Lazise and the “Dogana Veneta” (Customs house of Veneto) an elegant building built in 1300 from which Venezia controlled the trades on the Lake Garda for centuries.

Buses return to Verona from 22:00-22:30

Session Four Wednesday June 20

BUILDING AND ESCAPING

09:00-09:10 Andrea MAISNER and Richard COMPANS Chairpersons' remarks

43 09:10-09:30 Edward HUTCHINSON MOLECULAR ANATOMY OF THE INFLUENZA VIRION MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom 44 09:30-09:50 Rob RUIGROK ASSEMBLY AND STRUCTURE OF MEASLES VIRUS NUCLEOCAPSID PARTICLES IBS, Grenoble, France 45 09:50-10:00 Masahiro NAKANO ULTRASTRUCTURE OF THE INFLUENZA VIRUS RIBONUCLEOPROTEIN COMPLEXES PRODUCING VIRAL RNAs KYOTO UNIVERSITY, Kyoto, Japan 46 10:00-10:20 Yves GAUDIN NEGRI BODIES ARE VIRAL FACTORIES WITH PROPERTIES OF LIQUID ORGANELLES INSTITUT DE BIOLOGIE INTÉGRATIVE DE LA CELLULE, CNRS, Gif sur Yvette France 47 10:20-10:30 Emily BRUCE NEW TECHNIQUES TO VISUALIZE THE MAMMARENAVIRUS (LCMV) LIFE CYCLE REVEAL A RAB5C-POSITIVE COMPARTMENT AS A POTENTIAL SITE FOR GENOME REPLICATION AND VIRAL PARTICLE PRE-ASSEMBLY UNIVERSITY OF VERMONT, BURLINGTON, United States

COFFEE AND POSTER SESSION 10:30-11:30 WednesdayBUILDING AND ESCAPING June 19

48 11:30-11:50 Jason BOTTEN KEY LCMV-HOST INTERACTIONS REQUIRED FOR DEFECTIVE INTERFERING PARTICLE PRODUCTION AND THE HIGHLY DYNAMIC STATE OF VIRAL REPLICATION AND TRANSCRIPTION DURING PERSISTENCE. University of Vermont, Burlington, United States 49 11:50-12:00 Verena TE KAMP RESTRICTED INTRANEURONAL TRANSPORT OF FIELD RABIES VIRUS GLYCOPROTEIN FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany 50 12:00-12:20 Jacco BOON NUCLEOTIDE RESOLUTION MAPPING OF INFLUENZA A VIRUS NUCLEOPROTEIN-RNA INTERACTIONS REVEALS THE LANDSCAPE OF VIRAL RNA FEATURES REQUIRED FOR REPLICATION WASHINGTON UNIVERSITY, Saint Louis, United States 51 12:20-12:30 Naoki TAKIZAWA FINE MAPPING OF INFLUENZA A VIRUS INTRA AND INTERSEGMENT RNA INTERACTIONS INSTITUTE OF MICROBIAL CHEMISTRY (BIKAKEN), Tokyo, Japan 52 12:30-12:50 Seema LAKDAWALA VISUALIZING THE INTRACELLULAR ASSEMBLY OF INFLUENZA VIRAL RNA USING CONFOCAL AND LIGHT SHEET LIVE CELL MICROSCOPE UNIVERSITY OF PITTSBURGH, Pittsburgh, United States

LUNCH AND POSTERS 12:50-14:20

Session Five DAMAGING AND SPREADING

14:20-14:30 Anthony GRIFFITHS, Sandra DIEDERICH and Diane GRIFFIN Chairpersons' remarks

53 14:30-14:50 Charles RUSSELL HA STABILITY GOVERNS INFLUENZA A VIRUS REPLICATION, VIRULENCE, HOST RANGE, AND PANDEMIC POTENTIAL ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN 54 14:50-15:10 Stacey SCHULTZ-CHERRY IMPACT OF OBESITY ON INFLUENZA VIRUS; PATHOGENESIS, VIRAL POPULATIONS AND TRANSMISSION ST JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States 55 15:10-15:30 Paul DUPREX MULTIROUTE MORBILLIVIRUS ENTRY: DISEASE INFORMS VACCINE DELIVERY Boston University School of Medicine, Boston, United States 56 15:30-15:40 Daniel SCHNEPF INTERFERON LAMBDA PREVENTS THE SPREAD OF RESPIRATORY VIRUSES FROM THE UPPER RESPIRATORY TRACT TO THE LUNGS AND RESTRICTS VIRUS TRANSMISSION IN MICE MEDICAL CENTER UNIVERSITY OF FREIBURG. Freiburg im Breisgau, Germany 57 15:40-15:50 Judith OYMANS BREACHING THE OVINE PLACENTAL BARRIER BY RIFT VALLEY FEVER VIRUS WAGENINGEN BIOVETERINARY RESEARCH, Utrecht, Netherlands

COFFEE AND POSTERS 15:50-16:50 DAMAGING AND SPREADING

58 16:50-17:00 Jessica FIEGE MECHANISMS AND CONSEQUENCES OF CELLULAR SURVIVAL FROM INFLUENZA VIRUS INFECTION UNIVERSITY OF MINNESOTA, Minneapolis, United States 59 17:00-17:10 Taylor WEARY CHARACTERIZATION OF EBOLA VIRUS DEFECTIVE GENOMES IN THE TESTES OF PERSISTENTLY INFECTED NON-HUMAN PRIMATES TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States 60 17:10-17:20 Rik DE SWART STUDIES INTO THE MECHANISM OF MEASLES-ASSOCIATED IMMUNE SUPPRESSION DURING AN OUTBREAK OF MEASLES IN THE NETHERLANDS ERASMUS MC, Rotterdam, Netherlands 61 17:20-17:30 Cyrille MATHIEU VIRAL ENTRY PROPERTIES REQUIRED FOR FITNESS IN HUMANS REVEALED THROUGH RAPID GENOMIC CHANGE DURING VIRAL ISOLATION Columbia University Medical Center, New York, United States 62 17:30-17:50 Thomas PIETSCHMANN GENETIC DETERMINANTS OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN INFANTS TWINCORE- CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany 63 17:50-18:10 Gustavo PALACIOS THE EGYPTIAN ROUSETTE GENOME, PROVEN HOST FOR MARBURG VIRUS, REVEALS UNEXPECTED FEATURES OF BAT ANTIVIRAL IMMUNITY USAMRIID, Frederick, United States

FREEDOM OF VERONA Thursday June 21

DAMAGING AND SPREADING

64 09:00-09:20 Amy HARTMAN BIPHASIC VASCULAR BREAKDOWN AND INFLUX OF NEUTROPHILS INTO THE BRAIN DURING RIFT VALLEY FEVER VIRUS ENCEPHALITIS UNIVERSITY OF PITTSBURGH, Pittsburgh, United States 65 09:20-09:40 Ana FALCON CARDIAC DISORDERS AND SUDDEN DEATH CAUSED UPON HEART INFECTION BY HUMAN PATHOGENIC INFLUENZA A VIRUS CENTER FOR BIOMEDICAL RESEARCH (CIBER), Madrid, Spain 66 09:40-10:00 Aartjan TE VELTHUIS ABERRANT VIRAL RNAs LINK AVIAN AND PANDEMIC INFLUENZA VIRUS VIRULENCE TO ERRONEOUS RNA POLYMERASE ACTIVITY UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom 67 10:00-10:10 Jessica SCHULZE INFLUENZA A VIRUS M2 PROTEIN INTERACTS WITH CELLULAR NA,K- ATPASE: DOES IT HAVE A PATHOPHYSIOLOGICAL ROLE IN INFLUENZA PNEUMONIA? ROBERT KOCH INSTITUTE, Berlin, Germany 68 10:10-10:20 Hiroshi UEKI IN VIVO IMAGING CAPTURES THE PATHOPHYSIOLOGICAL CHANGES AND DYNAMICS OF IMMUNE CELLS IN INFLUENZA VIRUS-INFECTED MOUSE LUNG INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan

COFFEE AND POSTERS 10:20-11:10 Session Six FIGHTING AND RESPONDING

11:10-11:20 Sumit CHANDA, Maria Grazia CUSI and Hong JIN Chairpersons' remarks

69 11:20-11:40 Veronika VON MESSLING STOPPING MEASLES IN ITS TRACKS - EFFICACY OF AN ORALLY BIOAVAILABLE ANTIVIRAL AGAINST MEASLES VIRUS IN SQUIRREL MONKEYS PAUL-EHRLICH-INSTITUT, Langen, Germany 70 11:40-12:00 Travis WARREN REMDESIVIR (GS-5734) PROTECTS NONHUMAN PRIMATES AGAINST PATHOGENIC FILOVIRUSES US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States 71 12:00-12:10 Daniel GOLDHILL THE MECHANISM OF RESISTANCE TO FAVIPIRAVIR IN INFLUENZA Imperial College, London, United Kingdom 72 12:10-12:20 Shuzo URATA IDENTIFICATION OF CALCIUM CHANNEL BLOCKER AS AN ANTI-SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS (SFTSV) COMPOUND NAGASAKI UNIVERSITY, INSTITUTE OF TROPICAL MEDICINE, Nagasaki Japan 73 12:20-12:40 Paul WICHGERS SCHREUR BUNYAVIRUS VACCINE DEVELOPMENT BOOSTED BY NOVEL INSIGHTS INTO GENOME REPLICATION AND PACKAGING WAGENINGEN BIOVETERINARY RESEARCH, Lelystad, Netherlands

LUNCH AND POSTERS 12:40-13:50 FIGHTING AND RESPONDING

74 13:50-14:10 Katie DOORES CONVERGENT IMMUNOLOGICAL SOLUTIONS TO ARGENTINE HEMORRHAGIC FEVER VIRUS NEUTRALIZATION KING'S COLLEGE LONDON, London, United Kingdom 75 14:10-14:30 Johannes LANGEDIJK STRUCTURAL BASIS FOR RECOGNITION OF THE CENTRAL CONSERVED REGION OF RSV G BY NEUTRALIZING HUMAN ANTIBODIES JANSSEN VACCINES AND PREVENTION, Leiden, Netherlands 76 14:30-14:50 Kanta SUBBARAO HEADS WIN! HEAD-SPECIFIC B CELLS AND ANTIBODY DOMINATE THE IMMUNE RESPONSE IN A MISMATCHED PRIME-BOOST VACCINE STRATEGY THE PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia 77 14:50-15:00 Atsuhiro YASUHARA THE POTENTIAL OF HUMAN MONOCLONAL ANTIBODIES THAT RECOGNIZE THE INFLUENZA A(H1N1)PDM09 VIRUS HEMAGGLUTININ RECEPTOR-BINDING SITE AS ANTI-INFLUENZA AGENTS. INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, JAPAN 78 15:00-15:10 Miguel Angel MUNOZ ALIA COORDINATE DE-IMMUNIZATION OF MEASLES VIRUS ENVELOPE GLYCOPROTEINS DRIVES THE EMERGENCE OF ANTIGENIC VARIANTS MAYO CLINIC, ROCHESTER, United States

COFFEE AND POSTERS 15:10-16:00 FIGHTING AND RESPONDING

79 16:00-16:20 Ulla BUCHHOLZ LIVE-ATTENUATED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE CANDIDATE WITH NS2 DELETION AND GENETICALLY STABILIZED TEMPERATURE SENSITIVITY MUTATION IS SAFE, IMMUNOGENIC, AND GENETICALLY STABLE IN RSV SERONEGATIVE CHILDREN NIAID, NIH, Bethesda, United States 80 16:20-16:40 David WENTWORTH RESPONSE TO RE-EMERGENCE OF INFLUENZA A(H7N9) VIRUSES CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States 81 16:40-16:50 Oliver DIBBEN H1N1 VACCINE EFFECTIVENESS IN LIVE ATTENUATED INFLUENZA VACCINE IS DRIVEN BY VIRAL REPLICATIVE FITNESS IN THE HUMAN RESPIRATORY TRACT: SELECTION OF A NEW AND IMPROVED VACCINE CANDIDATE MEDIMMUNE, Liverpool, United Kingdom 82 16:50-17:00 Aliza KATZ LASSA VIRUS GLYCO-PROTEIN1 CONFORMATIONAL CHANGES – A POSSIBLE ROLE FOR IMMUNE EVASION WEIZMANN INSTITUTE, Jerusalem, Israel 83 17:00-17:20 Diane GRIFFIN MEASLES WILD TYPE AND VACCINE VIRUSES: REPLICATION AND IMMUNE RESPONSES IN RHESUS MACAQUES JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, United States

REMOVE SESSION TWO POSTERS UNREMOVED POSTERS AFTER 17.45 WILL BE DISCARDED!

GALA DINNER

BUSES DEPART GRAN GUARDIA 18:45

RETURN FROM 22:30-00:00 Gala Dinner

VILLA ARVEDI

Buses leave from the front of Gran Guardia at 18:45 Tonight we dine, dance and drink wines from the Vento region as we take a trip into the countryside to a beautiful 17th century mansion. Sip aperitifs on the porch, chat in the orangery and study the frescoed ceilings of this wonderful Italian villa. In the time honored tradition of NSV Meetings, the Gala Dinner is always something to remember!

Buses return to Verona from 22:30-00:00

Session Seven Friday June 22

EMERGING AND EVOLVING

09:30-09:40 Alain KOHL and Connie SCHMALJOHN Chairpersons' remarks

84 09:40-10:00 Jens KUHN MEGATAXONOMY OF NEGATIVE-SENSE RNA VIRUSES: PHYLUM “NEGARNAVIRICOTA” NIH/NIAID/DCR/INTEGRATED RESEARCH FACILITY AT FORT DETRICK, Frederick, United States 85 10:00-10:10 Hector MORENO BORREGO ISOLATION, CHARACTERIZATION, AND RAPID ADAPTATION OF TICK- BORNE ARENAVIRUS Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne (Switzerland) Switzerland 86 10:10-10:20 Rebecca JOHNSON CHARACTERISATION OF A NOVEL PARAMYXOVIRUS ISOLATED FROM PTEROPID BAT URINE CSIRO-AUSTRALIAN ANIMAL HEALTH LABORATORY, East Geelong, Australia 87 10:20-10:30 Mukai YAHIRO INVESTIGATION OF THE BIOLOGICAL ROLE OF AN ENDOGENOUS BORNAVIRUS-LIKE ELEMENT IN MINIOPTERID BAT GENOMES INSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES , KYOTO UNIVERSITY, Kyoto, Japan 88 10:30-10:50 Branka HORVAT NIPAH VIRUS W PROTEIN MODULATES THE NF-ΚB SIGNALING PATHWAY BY TARGETING A HOST SCAFFOLD PROTEIN CIRI, Lyon, France

COFFEE 10:50-11:30 FridayEMERGING AND June EVOLVING 22

89 11:30-11:50 John STEEL AVIAN INFLUENZA VIRUS M SEGMENT GENE EXPRESSION IS DYSREGULATED IN MAMMALIAN CELLS, LEADING TO A BLOCK IN AUTOPHAGY AND RESTRICTED VIRAL GROWTH EMORY UNIVERSITY, Atlanta, United States 90 11:50-12:00 Kevin CIMINSKI ASSESSMENT OF THE ZOONOTIC POTENTIAL OF THE BAT INFLUENZA A VIRUS H18N11 UNIVERSITY MEDICAL CENTER FREIBURG CENTER FOR MICROBIOLOGY AND HYGIENE INSTITUTE OF VIROLOGY, Freiburg, Germany 91 12:00-12:10 Cyril LENOUEN SELECTIVE PRESSURE ON RESPIRATORY SYNCYTIAL VIRUS BEARING CODON-PAIR DEOPTIMIZED F AND G ORFS GENERATES INTERNAL- DELETION GENOMES THAT PARADOXICALLY RESCUE VIRAL REPLICATION NIH/NIAID/LID, BETHESDA, United States 92 12:10-12:20 Maino TAHARA A NEW OPTICALLY CONTROLLABLE MEASLES VIRUS VECTOR NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan 93 12:20-12:40 Benjamin TENOEVER LOSS OF RNAi WAS REQUIRED FOR THE INVENTION OF NEGATIVE- STRANDED RNA VIRUSES ICAHN SCHOOL OF MEDICINE, New York, United States

12:40-12:45 CLOSING REMARKS

LUNCH WITH WINE

Poster Session One

Poster Prizes:

We are grateful to the Microbiology Society and the Journal of General Virology, Nature Microbiology, Nature Reviews in Microbiology and The European Society for Virology for sponsoring seven posters prizes. If you are an early career researcher who would like your research considered for an award just put the heart shaped sticker you’ll find in the conference bag beside your poster to let the judges know. BREAKING AND ENTERING P001 Jeremy Luban INSIGHT INTO THE FUSION MECHANISM GLEANED FROM AN EBOLA VIRUS GLYCOPROTEIN MUTANT THAT DOMINATED THE 2013-2016 PANDEMIC UNIVERSITY OF MASSACHUSETTS MED SCHOOL, Worcester, United States P002 Masato Tsurudome THE HEMAGGLUTININ-NEURAMINIDASE (HN) HEAD DOMAIN AND THE FUSION (F) PROTEIN STALK DOMAIN OF THE PARAINFLUENZA VIRUSES AFFECT THE SPECIFICITY OF THE HN-F INTERACTION CHUBU UNIVERSITY, Kasugai, Japan P003 Dalan Bailey STRUCTURE-GUIDED IDENTIFICATION OF MORBILLIVIRUSES WITH ZOONOTIC POTENTIAL The Pirbright Institute Guildford, United Kingdom P004 Lauren Byrd-Leotis NATURAL GLYCAN RECEPTORS FOR INFLUENZA VIRUS IN HUMAN LUNG HARVARD MEDICAL SCHOOL, Boston, United States P005 Gert Zimmer THE CRITICAL ROLE OF HEMAGGLUTININ (HA) IN TRANSMISSION OF DUCK-ORIGIN H5NX LOW-PATHOGENIC AVIAN INFLUENZA VIRUSES IN CHICKENS INSTITUTE OF VIROLOGY AND IMMUNOLOGY (IVI), Mittelhäusern, Switzerland P006 Megan Slough TWO POINT MUTATIONS IN THE HANTAAN VIRUS GLYCOPROTEIN COMPLEX AFFORD THE GENERATION OF A HIGHLY INFECTIOUS REPLICATION-COMPETENT RECOMBINANT VSV ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States P007 Giulia Torriani HANTAVIRUS ENTRY INTO HUMAN RESPIRATORY EPITHELIAL CELLS INVOLVES MACROPINOCYTOSIS UNIVERSITY HOSPITAL CENTER AND UNIVERSITY OF LAUSANNE, Lausanne, Switzerland P008 Jennifer Mayor HANTAVIRUSES ENTER INTO HUMAN AIRWAY EPITHELIUM USING PHOSPHATIDYLSERINE RECEPTORS TIM-1 AND AXL LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland P009 Rhys Pryce STRUCTURAL BASIS FOR DIFFERENTIAL EPHRIN-MEDIATED HOST-CELL ENTRY PATHWAYS OF HENIPAVIRUSES DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom P010 Tatsunari Kondoh SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN NIEMANN-PICK C1 INFLUENCE ENTRY OF FILOVIRUSES INTO CELLS DIVISION OF GLOBAL EPIDEMIOLOGY, RESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan P011 Michael Herren DUAL-REGULATORY ROLE OF THE MORBILLIVIRUS ATTACHMENT PROTEIN HEAD-TO- STALK LINKER MODULE IN MEMBRANE FUSION TRIGGERING University of Bern, Bern, Switzerland P012 Manasi Ajit Tamhankar EBOLA VIRUS ENTRY AND EGRESS IN POLARIZED EPITHELIAL CELLS TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States P013 Yves Gaudin BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF VSV (NEW JERSEY STRAIN) GLYCOPROTEIN INSTITUT DE BIOLOGIE INTÉGRATIVE DE LA CELLULE, CNRS, Gif sur Yvette, France P014 Annelies Stevaert INFLUENZA VIRUS ENTRY VIA INTERPLAY BETWEEN PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA AND GM3 GANGLIOSIDE: A VALID ROUTE FOR HOST- TARGETED ANTIVIRAL INTERVENTION Rega Institute for Medical Research, KU Leuven – University of Leuven, Leuve, Belgium P015 Nadine Krüger VIRAL ENTRY AND REPLICATION OF BAT-DERIVED MUMPS VIRUS University of Veterinary Medicine Hannover, Hannover, Germany P016 Mark J.G. Bakkers A GENOME-WIDE GENETIC SCREEN UNCOVERS A ROLE FOR HEPARAN SULFATE IN LCMV ENTRY HARVARD MEDICAL SCHOOL, Boston, United States P017 Lara M Kleinfelter CHARACTERIZATION OF HANTAVIRUS ENTRY THROUGH LIVE-CELL IMAGING ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States P018 Weng Ming Ng STRUCTURAL CLASSES OF OLD WORLD ARENAVIRUS GP1 ATTACHMENT GLYCOPROTEIN Division of Structural Biology, University of Oxford, Oxford, United Kingdom P019 Robert Stass ARCHITECTURE OF THE METASTABLE HANTAVIRUS ENVELOPE STRUBI, UNIVERSITY OF OXFORD, Oxford, United Kingdom P020 Svenja Mareike Wiechert CHARACTERIZATION OF DETERMINANTS FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS SPECIES SPECIFIC CELL ENTRY TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany P021 Kristopher Azarm THE NOVEL CEDAR HENIPAVIRUS ATTACHMENT GLYCOPROTEIN DISPLAYS IDIOSYNCRATIC USAGE OF THE HUMAN EPHRIN CELL SURFACE RECEPTORS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States P022 Emma Punch POTASSIUM ACTIVATES THE FUSION MACHINERY OF HAZARA VIRUS THROUGH SPIKE CONFORMATIONAL CHANGE University of Leeds, United Kingdom EXPRESSING AND MULTIPLYING P023 Edward Hutchinson COMPETING LYSINE MODIFICATIONS IN INFLUENZA VIRUS PROTEINS. MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom P024 Ming Luo ROLE OF THE NUCLEOCAPSID IN REGULATION OF VIRAL RNA SYNTHESIS GEORGIA STATE UNIVERSITY, Atlanta, United States P025 Withdrawn P026 Thibaut Crepin NUCLEAR IMPORT AND ASSEMBLY OF INFLUENZA VIRUS REPLICATION MACHINERY IBS, Univ. Grenoble Alpes, CEA, CNRS, Grenoble, France P027 Jean-Francois Eleouet DEPHOSPHORYLATION OF RESPIRATORY SYNCYTIAL M2-1 PROTEIN BY THE CELLULAR PHOSPHATASE PP1 IS REQUIRED FOR ITS mRNA BINDING ABILITY INRA, Jouy en Josas, France P028 Jean-Francois Eleouet THE ISOLATION AND CHARACTERIZATION OF A N°-P COMPLEX OF THE RESPIRATORY SYNCYTIAL VIRUS OPENS THE WAY TO THE RATIONAL DESIGN OF NEW ANTIVIRALS INRA, Jouy en Josas, France P029 Bo Liang MECHANISM OF RESPIRATORY SYNCYTIAL VIRUS RNA SYNTHESIS EMORY UNIVERSITY SCHOOL OF MEDICINE, Atlanta, United States P030 Gaya Amarasinghe STRUCTURAL BASIS FOR REGULATION OF FILOVIRAL NUCLEOPROTEIN (NP) BY VP35 DURING VIRAL RNA SYNTHESIS WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States P031 Kah-Whye Peng FIRST IN HUMAN STUDIES OF ONCOLYTIC VESICULAR STOMATITIS VIRUSES ENCODING INTERFERON FOR CANCER THERAPY MAYO CLINIC, Rochester, United States P032 Elizabeth Sloan START-SNATCHING: A POTENTIAL NOVEL MECHANISM FOR TRANSLATION INITIATION IN SEGMENTED NEGATIVE-SENSE RNA VIRUSES CVR-UNIVERSITY OF GLASGOW, Glasgow, United Kingdom P033 Maria Rosenthal STRUCTURAL INSIGHTS INTO REPTARENAVIRUS CAP-SNATCHING MACHINERY BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany P034 Itziar Serna Martin A MECHANISM FOR THE ACTIVATION OF THE INFLUENZA VIRUS TRANSCRIPTASE UNIVERSITY OF OXFORD, Oxford, United Kingdom P035 Kohei Oishi N-TERMINAL ACETYLATION BY NATB IS REQUIRED FOR THE SHUTOFF ACTIVITY OF INFLUENZA A VIRUS PA-X UNIVERSITY OF TOKYO, Minato-ku, Japan P036 Yuki Takamatsu IDENTIFICATION OF AN EBOLA VIRUS VP30-SPECIFIC KINASE THAT REGULATES VIRAL TRANSCRIPTION INSTITUTE OF VIROLOGY, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany P037 Janne Tynell FUNCTIONAL CHARACTERIZATION OF THE HANTAVIRUS S SEGMENT UNTRANSLATED REGION KAROLINSKA INSTITUTET, Stockholm, Sweden P038 Denis Gerlier DETAILED MAPPING OF THE VARIOUS POLYMERASE COFACTOR FUNCTIONS WITHIN THE PHOSPHOPROTEIN OF MEASLES VIRUS CIRI INSERM U1111, CNRS UMR5307, UNIVERSITY LYON 1, ENS LYON, UNIV LYON, Lyon, France P039 Marie-Anne Rameix-Welti VIRAL TRANSCRIPTION DRIVES THE FORMATION OF VIRAL RNA GRANULES WITHIN RESPIRATORY SYNCYTIAL VIRUS INCLUSION BODIES VERSAILLES SAINT QUENTIN UNIVERSITY, MONTIGNY-LE-BRETONNEUX, France P040 Bernard Delmas INFLUENZA VIRUS RNA-POLYMERASE: TEMPERATURE-SENSITIVE MUTANTS IN PB1 DISPLAY A DEFECT IN NUCLEAR TARGETING OF THE PA-PB1 DIMER INRA, Jouy-en-Josas, France P041 Monique Spronken OPTIMISING INFLUENZA A REPORTER VIRUSES BY IN VIVO PASSAGING ERASMUS MEDICAL CENTRE, Rotterdam, Netherlands P042 Timothy James Mottram RIFT VALLEY FEVER PHLEBOVIRUS NUCLEOPROTEIN PROTEOMIC STUDIES IDENTIFY IMPORTANT WNT PATHWAY INTERACTIONS MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom P043 Jacquline Carson Risalvato IDENTIFICATION OF MUMPS VIRUS NUCLEOPROTEIN RESIDUE ENHANCES PRODUCTION OF DEFECTIVE INTERFERING PARTICLES UNIVERSITY OF GEORGIA, Athens, United States P044 Shohei Kojima ALTERNATIVE SPLICING UNMASKS AN ENDOPLASMIC RETICULUM TARGETING SIGNAL OF BORNA DISEASE VIRUS NUCLEOPROTEIN KYOTO UNIVERSITY, Kyoto, Japan P045 Alexander Koehler THE OLIGOMERIC STATE OF MARBURG VIRUS VP40 INFLUENCES ITS ROLE IN MODULATING VIRAL TRANSCRIPTION AND REPLICATION PHILIPPS UNIVERSITY MARBURG, Marburg, Germany P046 Andre Bertran TOWARDS THE DEVELOPMENT OF REVERSE GENETICS SYSTEMS FOR TOMATO SPOTTED WILT VIRUS WAGENINGEN UNIVERSITY, Wageningen, Netherlands P047 Nadine Biedenkopf ROLE OF HOST PHOSPHATASE PP2A IN FILOVIRUS REPLICATION CYCLE PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany P048 Max Renner STRUCTURAL CHARACTERISATION OF THE METAPNEUMOVIRUS TRANSCRIPTASE COMPONENTS P AND M2-1 BY MODELLING, CRYSTALLOGRAPHY, AND SAXS UNIVERSITY OF OXFORD, Oxford, United Kingdom P049 Natasha Louise Tilston-Lunel CHARACTERIZING DEFECTIVE VIRAL GENOMES OF CANINE DISTEMPER VIRUS BOSTON UNIVERISTY, Boston, United States P050 Joshua Horwitz RABIES VIRUS L-PROTEIN C-TERMINAL DOMAINS ARE STRUCTURALLY COORDINATED BY THE N-TERMINUS OF THE VIRAL PHOSPHOPROTEIN HARVARD MEDICAL SCHOOL, Boston, United States P051 Charles-Adrien Richard EFFECT OF MUTATIONS IN THE GENE-END SEQUENCE ON RSV TRANSCRIPTION INRA, Jouy en Josas, France P052 Koyu Hara THE C-TERMINAL FRAGMENT OF THE RESPIRATORY SYNCYTIAL VIRUS PHOSPHOPROTEIN INHIBITS THE VIRAL POLYMERASE ACTIVITY KURUME UNIVERSITY SCHOOL OF MEDICINE, Kurume, Japan P053 Akihiro Sugai INVESTIGATION OF A PROTEIN KINASE RESPONSIBLE FOR THE PHOSPHORYLATION OF MEASLES VIRUS NUCLEOPROTEIN THE UNIVERSITY OF TOKYO, Tokyo, Japan P054 Ashley Lauren Silvia DISCOVERY AND DETECTION OF EBOV-ENCODED MICRORNA-LIKE MOLECULES IN INFECTED CELLS AND NON-HUMAN PRIMATES TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States P055 Christophe Cardone STRUCTURAL CHARACTERIZATION OF RSV PHOSPHOPROTEIN CNRS ICSN, Gif-sur-Yvette Cedex, France P056 Alex Walker DETECTION AND CHARACTERISATION OF INFLUENZA VIRUS RNA POLYMERASE DIMERS USING BIMOLECULAR FLUORESCENCE COMPLEMENTATION (BIFC) University of Oxford, United Kingdom P057 Joseph Gould THE CONNECTOR DOMAIN OF VESICULAR STOMATITIS VIRUS LARGE PROTEIN IS AN ACCEPTOR SITE FOR PHOSPHOPROTEIN BINDING UNIVERSITY OF ALABAMA AT BIRMINGHAM, Birmingham, United States P058 Antoine SCHRAMM MEASLES VIRUS PHOSPHOPROTEIN MULTIMERIZATION DOMAIN: COILED-COIL FEATURES AND FUNCTION AFMB CNRS, Marseille, France P059 Boris Bogdanow COMBINED PROTEOMICS AND TRANSCRIPTOMICS SUGGESTS THAT M1 mRNA SPLICING INFLUENCES IAV HOST SPECIFICITY MDC BERLIN, Berlin, Germany

SUPPRESSING AND CONQUERING

P060 Atsushi Kawaguchi MXA-DEPENDENT INFLAMMASOME RESTRICTS INFLUENZA A VIRUS INFECTION IN RESPIRATORY EPITHELIAL CELLS UNIVERSITY OF TSUKUBA, Tsukuba, Japan P061 Ronald Dijkman CHARACTERIZATION OF VIRUS - HOST INTERACTION DYNAMICS WITHIN THE RESPIRATORY EPITHELIUM INSTITUTE OF VIROLOGY AND IMMUNOLOGY IVI, Bern, Switzerland P062 Yan Zhou NUCLEAR RESIDENT RIG-I SENSES INFLUENZA A VIRUS REPLICATION MOUNTING AN ANTIVIRAL RESPONSE UNIVERSITY OF SASKATCHEWAN, Saskatoon, Canada P063 Toru Takimoto SPECIFICITY AND FUNCTIONAL INTERPLAY BETWEEN INFLUENZA VIRUS PA-X AND NS1 SHUTOFF ACTIVITY UNIVERSITY OF ROCHESTER MEDICAL CENTER, Rochester, United States P064 Georg Herrler THE AIRWAY EPITHELIUM MAINTAINS THE BARRIER FUNCTION AFTER INFLUENZA VIRUS INFECTION DESPITE THE EXTENSIVE LOSS OF CILIATED CELLS STIFTUNG TIERÄRZTLICHE HOCHSCHULE HANNOVER, Hannover, Germany P065 Stefan Pöhlmann INSIGHTS INTO TETHERIN COUNTERACTION BY THE EBOLA VIRUS GLYCOPROTEIN GERMAN PRIMATE CENTER, Göttingen, Germany P066 David L V Bauer INFLUENZA VIRUS MOUNTS A TWO-PRONGED ATTACK ON RNA POLYMERASE II TRANSCRIPTION UNIVERSITY OF OXFORD, Oxford, United Kingdom P067 Christian Karl Pfaller FLYING UNDER THE (R)ADAR: ADAR1-P150 EDITING COUNTERACTS INTRINSIC IMMUNITY ACTIVATION BY SELF AND VIRAL DOUBLE STRANDED RNA MAYO CLINIC, Rochester, United States P068 Laura Martin-Sancho GLOBAL SIRNA SCREEN IN HUMAN MACROPHAGES IDENTIFY TBC1D5 AS A NOVEL CELLULAR RESTRICTION FACTOR FOR INFLUENZA A VIRUS REPLICATION SBP Medical Discovery Institute, San Diego, United States P069 Shashank Tripathi INTERFERENCE BEFORE INTERFERON: CHARACTERIZATION OF INTERFERON SIGNALING INDEPENDENT ANTIVIRAL INNATE IMMUNITY AGAINST INFLUENZA A VIRUSES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States P070 Jonathan Colin Guito COMPARATIVE TRANSCRIPTOMICS REVEAL THAT ANTIVIRAL GENE EXPRESSION IN THE EGYPTIAN ROUSETTE BAT IS ANTAGONIZED IN VITRO BY MARBURG VIRUS INFECTION CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P071 Anna Bruchez TRANSPOSON-MEDIATED ACTIVATION SCREENING IN HUMAN CELLS IDENTIFIES THE CLASS II TRANSACTIVATOR AS A RESTRICTION FACTOR FOR EBOLA BENAROYA RESEARCH INSTITUTE, Seattle, United States P072 Jelena Andrejeva PARAINFLUENZA VIRUS 5 (PIV5) P PROTEIN IS MODIFIED IN RESPONSE TO IFNΑ, AND THIS INHIBITS PIV5 INFECTION UNIVERSITY OF ST. ANDREWS, SCOTLAND, UK St. Andrews, United Kingdom P073 Megan R. Edwards STRUCTURAL BASIS OF IMPORTIN ALPHA SPECIFICITY FOR HENIPAVIRUS W PROTEINS GEORGIA STATE UNIVERSITY, Atlanta, United States P074 Agnieszka Szemiel PUUMALA HANTAVIRUS INFECTION MODULATES THE CIRCADIAN CLOCK MRC - University of Glasgow Centre for Virus Research, Glasgow, United Kingdom P075 Kristina L. Schierhorn HUR RESTRICTS EBOLA VIRUS REPLICATION KING'S COLLEGE LONDON, London, United Kingdom P076 Sara Clohisey TERMINAL DEPTH SINGLE-MOLECULE SEQUENCING OF CAPPED TRANSCRIPTS REVEALS HOST-PATHOGEN DYNAMICS IN HUMAN MACROPHAGES. THE ROSLIN INSTITUTE, Edinburgh, United Kingdom P077 Rokusuke Yoshikawa IS THE PATHOGENICITY OF SFTSV DETERMINED BY VIRAL NSS PROTEIN? NAGASAKI UNIVERSITY, Nagasaki-shi, Japan P078 Julianna Han REGULATION OF CELL INTRINSIC IMMUNITY BY THE TRANSCRIPTIONAL REPRESSOR CAPICUA THE UNIVERSITY OF CHICAGO, Chicago, United States P079 Kai Rogers ACUTE PLASMODIUM INFECTION PROMOTES RESISTANCE TO EBOLA VIRUS VIA TYPE 1 IMMUNITY IN MACROPHAGES UNIVERSITY OF IOWA, Iowa City, United States P080 Miyu Moriyama RECOGNITION OF INFLUENZA A VIRUS BY DNA SENSORS UNIVERSITY OF TOKYO, Tokyo, Japan P081 Diego Cantoni REGULATION OF CELL DEATH BY THE EBOLAVIRUS VP24 PROTEIN UNIVERSITY OF KENT, Canterbury, United Kingdom P082 Withdrawn P083 Jennifer Wuerth SANDFLY FEVER SICILIAN VIRUS NSS SPECIFICALLY TARGETS IRF3 TO INHIBIT TYPE I INTERFERON INDUCTION JUSTUS-LIEBIG UNIVERSITY GIESSEN, Giessen, Germany P084 Rute Maria Pinto IDENTIFICATION OF TWO NEW POLYPEPTIDES FROM SEGMENT 2 OF IAV THAT MODULATE THE TYPE I INTERFERON RESPONSE THE ROSLIN INSTITUTE, THE UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom P085 Colleen Jonsson EARLY HOST RESPONSES OF HUMAN PRIMARY LUNG MICROVASCULAR ENDOTHELIAL CELLS AND RESTING MONOCYTES TO BLACK CREEK CANAL ORTHOHANTAVIRUS (BCCV) UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Memphis, United States P086 Takeshi Ichinohe TWO CONSERVED AMINO ACIDS WITHIN THE NSS PROTEIN OF SFTS VIRUS ARE ESSENTIAL FOR ANTI-INTERFERON ACTIVITY UNIVERSITY OF TOKYO, Tokyo, Japan P087 Withdrawn P088 Saori Sakabe ANATOMY OF CYTOTOXIC T LYMPHOCYTE RESPONSE DURING THE 2013-2016 EBOLA OUTBREAK IN WEST AFRICA THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States P089 Stéphanie Devignot THE OVARIAN TUMOR (OTU) DOMAIN OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS (CCHFV) INFLUENCES THE POLYMERASE RDRP ACTIVITY, BUT DOES NOT COUNTERACT INNATE IMMUNITY INSTITUTE FOR VIROLOGY, FB10 VETERINARY MEDICINE, Giessen, Germany P090 Asuka Yoshida NIPAH VIRUS C PROTEIN INHIBITS INFLAMMATORY CYTOKINE INDUCTION BY INTERACTION WITH PHOSPHATASE 2A INHIBITOR. THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan P091 Olivier Moncorgé MX1 REQUIREMENTS FOR INFLUENZA A VIRUS RESTRICTION IRIM, MONTPELLIER, France P092 Claudia Gandolfo UBIQUITINATION OF TOSCANA VIRUS NSS UNDERMINES ITS STABILITY AND HAS A ROLE IN RIG-I DEGRADATION University of Siena, Siena, Italy P093 Markus Hoffmann THE GLYCOPROTEIN OF VESICULAR STOMATITIS VIRUS IS A TETHERIN ANTAGONIST IN TRANSFECTED BUT NOT INFECTED CELLS DEUTSCHES PRIMATENZENTRUM GMBH, LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, Göttingen, Germany P094 Keisuke Ohta HUMAN PARAINFLUENZA VIRUS TYPE 2 V PROTEIN INDUCES FILAMENTOUS ACTIN FORMATION WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan P095 Yusuke Matsumoto REGULATION OF HAZARA VIRUS GROWTH THROUGH APOPTOSIS INHIBITION BY VIRAL NUCLEOPROTEIN SCHOOL OF MEDICINE, WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan P096 Hiroki Sato MEASLES VIRUS INFECTION TRIGGERS cGAS-DEPENDENT ANTIVIRAL RESPONSES. INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan P097 Valentina Volchkova EBOLA VIRUS INHIBITS CELLULAR NRF2-DEPENDENT ANTIOXIDANT SIGNALING PATHWAY VIA EXPRESSION OF STRUCTURAL PROTEIN VP24. CIRI 1111, Lyon, France P098 Tomoyuki Honda SMALL RNAS DERIVED FROM AN ENDOGENOUS BORNAVIRUS ELEMENT IN MICE SUPPRESS EXPRESSION OF A REPORTER WITH BORNA DISEASE VIRUS SEQUENCES IN GC2 CELLS OSAKA UNIVERISTY, Osaka, Japan P099 Withdrawn P100 Jorge Vera Otarola THE NSS PROTEIN FROM THE ANDES VIRUS INHIBITS THE TYPE I IFN RESPONSE PATHWAY LABORATORIO DE VIROLOGÍA MOLECULAR, INSTITUTO MILENIO DE INMUNOLOGÍA E INMUNOTERAPIA, CENTRO DE INVESTIGACIONES MÉDICAS, DEPARTAMENTO DE ENFERMEDADES INFECCIOSAS E INMUNOLOGÍA PEDIÁTRICA , ESCUELA DE MEDICINA, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE, Santiago, Chile P101 Sangjoon Lee INFLUENZA A VIRUS INFECTION TRIGGERS PYROPTOSIS AND APOPTOSIS OF RESPIRATORY EPITHELIAL CELLS THROUGH TYPE I IFN SIGNALING PATHWAY IN A MUTUALLY EXCLUSIVE MANNER UNIVERSITY OF TSUKUBA, Tsukuba, Japan P102 Whitney Manhart DEVELOPMENT OF AN EBOLA VIRUS INFECTION MODEL USING IPSC-DERIVED HEPATOCYTES BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States P103 Simone Lau KNOCKING ON THE NUCLEAR DOOR: RIFT VALLEY FEVER VIRUS VIRULENCE FACTOR NSS TARGETS NUCLEAR-CYTOPLASMIC TRANSPORT Justus-Liebig University, Giessen, Germany P104 Eline Soetens SINGLE DOMAIN ANTIBODIES TO PROBE THE ANTIVIRAL FUNCTION OF INTERFERON- INDUCED MX1 PROTEINS VIB/UGENT, Anzegem, Belgium P105 Mako Yanai INVOLVEMENT OF ADAR2 IN BORNA DISEASE VIRUS INFECTION KYOTO UNIVERSITY, Kyoto, Japan BUILDING AND ESCAPING P106 Withdrawn P107 Tao Deng CHARACTERIZATION OF THE H1 SUBTYPE-SPECIFIC NONCODING REGIONS OF INFLUENZA A VIRUSES IN REGULATING HA SEGMENT VIRION INCORPORATION INSTITUTE OF PATHOGEN BIOLOGY,CHINESE ACADEMY OF MEDICAL SCIENCES, Beijing, China P108 Rafael A. Medina THE COMPLEXITY OF THE N-GLYCOSYLATIONS NEAR SITE SA ON THE HA OF THE INFLUENZA A MODULATE ITS ANTIGENIC PROPERTY AND THE AVIDITY FOR ITS RECEPTOR PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, Santiago, Chile P109 Withdrawn P110 Marc Ringel ASSEMBLY AND SPREAD OF NIPAH VIRUS ENCODING A MATRIX PROTEIN WITH A DEFECTIVE NUCLEAR EXPORT SIGNAL PHILIPPS-UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany P111 Yvonne Börgeling TYROSINE 132 OF INFLUENZA A VIRUS MATRIX PROTEIN 1 IS ESSENTIAL FOR EFFICIENT VIRAL GENOME PACKAGING AND PARTICLE ASSEMBLY UNIVERSITY OF MUENSTER, Münster, Germany P112 Christopher Ziegler ARENAVIRUS EXIT, UBIQUITIN, AND THE ESCRT PATHWAY UNIVERSITY OF VERMONT, Burlington, United States P113 Olga Dolnik THE IQGAP FAMILY PROTEINS IN MARBURG VIRUS INFECTION PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany P114 Sho Miyamoto THE VRNA-VRNA INTERACTIONS IMPORTANT FOR HA VRNA PACKAGING OF THE INFLUENZA A VIRUS INSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES, KYOTO UNIVERSITY, Kyoto, Japan P115 Bernadeta Dadonaite ANALYSIS OF HIGHER ORDER RNA STRUCTURES IN THE INFLUENZA A VIRUS GENOME UNIVERSITY OF OXFORD, Oxford, United Kingdom P116 Matthew Badham THE INFLUENZA VIRUS M2 PROTEIN CYTOPLASMIC TAIL INTERACTS WITH HOST PROTEINS TO FACILITATE VIRAL MORPHOGENESIS. UNIVERSITY OF KENT, Canterbury, United Kingdom P117 Carina Conceicao EVIDENCE FOR A LINK BETWEEN BUDDING MORPHOLOGY AND TRANSMISSION OF AVIAN INFLUENZA A VIRUSES THE ROSLIN INSTITUTE, UNIVERSITY OF EDINBURGH, Roslin, United Kingdom P118 Sarah Fehling CHARACTERIZATION OF THE MOLECULAR MECHANISMS UNDERLYING INTERACTION OF LASSA VIRUS Z PROTEIN WITH THE HOST FACTOR KIF13A PHILIPPS UNIVERSITY MARBURG, Marburg, Germany P119 Fumitaka Momose ACCESSIBILITY ASSESSMENT OF THE TERMINAL REGION OF INFLUENZA A VIRUS GENOME SEGMENT BY FLUORESCENCE IN SITU HYBRIDIZATION KITASATO UNIVERSITY, Minato-ku, Japan P120 Takashi Irie DETAILED FUNCTIONAL MAPPING OF THE PARAMYXOVIRUS ACCESSORY PROTEINS IN VIRAL INFECTION HIROSHIMA UNIVERSITY, Hiroshima, Japan P121 Maria Günther INFLUENCE OF NUCLEAR LOCALIZATION SITES IN HENDRA VIRUS MATRIX PROTEIN ON INTERACTION WITH ANP32B AND VIRUS LIKE PARTICLE FORMATION Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany P122 Nicole Kadzioch SURFACE-EXPOSED LYSINE RESIDUES OF THE CDV MATRIX PROTEIN CONTRIBUTE TO MEMBRANE ASSOCIATION AND BUDDING ACTIVITY University of Bern, Vetsuisse Faculty, Bern, Switzerland P123 Matthieu Gast INVESTIGATION OF Α-HELICES OF CANINE DISTEMPER VIRUS MATRIX PROTEIN IN OLIGOMERIZATION AND MEMBRANE BUDDING ACTIVITY University of Bern Vetuisse Faculty, Bern, Switzerland

Poster Session Two

Poster prizes provided by: DAMAGING AND SPREADING P124 Chieko Kai A RECOMBINANT MEASLES VIRUS BLIND TO SLAM IS A PROMISING CANDIDATE FOR SCIRRHOUS GASTRIC CANCER THERAPY THE UNIVERSITY OF TOKYO, Tokyo, Japan P125 Amy Hartman RIFT VALLEY FEVER VIRUS INFECTION OF PREGNANT SPRAGUE-DAWLEY RATS RESULTS IN FETAL INFECTION AND DEMISE UNIVERSITY OF PITTSBURGH, Pittsburgh, United States P126 Douglas J. LaCount GENOME-WIDE ANALYSES OF FILOVIRUS-HOST CELL PROTEIN-PROTEIN INTERACTIONS PURDUE UNIVERSITY, West Lafayette, United States P127 Georg Herrler INFLUENZA VIRUSES AND PARAMYXOVIRUSES ENHANCE THE ADHERENCE AND INVASION PROPERTIES OF STREPTOCOCCI BY A SIALIC ACID-DEPENDENT INTERACTION WITH THE CAPSULAR POLYSACCHARIDE STIFTUNG TIERÄRZTLICHE HOCHSCHULE HANNOVER, Hannover, Germany P128 Angela Rasmussen SEX-DEPENDENT HOST RESPONSES ASSOCIATED WITH EBOLA VIRUS PATHOGENICITY COLUMBIA UNIVERSITY, New York, United States P129 Withdrawn P130 Alexander Ghanem WHOLE GENOME CRISPR/CAS9-KO SCREEN REVEALS PROTEIN KINASE R (PKR) AS THE KEY PLAYER IN RABIES VIRUS CYTOTOXICITY LMU MUNICH, Munich, Germany P131 Brian Hua FUNCTIONAL ANALYSIS OF A CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS GENOME FROM TICKS IDENTIFIES A GLYCOPROTEIN VARIANT THAT POORLY INFECTS HUMAN CELLS CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P132 Stephen R Welch TISSUE TROPISM AND DISSEMINATION OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IN IFNAR KNOCKOUT MICE VISUALIZED BY IN SITU FLUORESCENT IMAGING CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P133 Lisa Oestereich HUMAN IMMUNE RESPONSES TO LASSA VIRUS INFECTION IN NIGERIA BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany P134 Shadia Omar IDENTIFICATION OF ESCAPE MUTANTS OF EQUINE INFLUENZA USING POLYCLONAL SERA AND MONOCLONAL ANTIBODIES: A POTENTIAL ANTIGENIC DRIFT WITH AN IMPACT ON VACCINE EFFICACY ANIMAL HEALTH TRUST, Newmarket, United Kingdom P135 Seiya Yamayoshi IDENTIFICATION OF AMINO ACIDS THAT ENHANCE VIRUS REPLICATION IN MAMMALIAN HOSTS IN THE PB2 AND PA PROTEINS OF A HIGHLY PATHOGENIC H7N9 INFLUENZA VIRUS ISOLATED FROM A HUMAN INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan P136 Joanna Pulit-Penaloza COMPARATIVE IN VITRO AND IN VIVO ANALYSIS OF SWINE-ORIGIN H1N1 AND H1N2 INFLUENZA VIRUSES ISOLATED FROM HUMAN CASES BETWEEN 2011 AND 2016. CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P137 Tomoko Fujiyuki ONCOLYTIC RECOMBINANT MEASLES VIRUS IS A CANDIDATE THERAPEUTIC AGENT FOR REFRACTORY BREAST CANCER THE UNIVERSITY OF TOKYO, Tokyo, Japan P138 Stephanie Reynard SPECIFIC IMMUNOLOGICAL SIGNATURE DEPENDING ON THE DISEASE OUTCOME IN EBOLA VIRUS-INFECTED PATIENTS FROM MACENTA (GUINEA) INSTITUT PASTEUR, Lyon, France P139 Shotaro Uchida MEASLES VIRUS V PROTEIN CONTRIBUTES TO THE TRANSPORT OF NUCLEOPROTEIN COMPLEXES AND EFFICIENT VIRAL ASSEMBLY IN NEURONAL CELLS JAPAN, Tokyo, Japan P140 Kathleen Cashman EVIDENCE OF VIRAL PERSISTENCE IN CYNOMOLGUS MACAQUES THAT SURVIVE PARENTERAL EXPOSURE WITH LASSA FEVER VIRUS THE GENEVA FOUNDATION / USAMRIID, Fort Detrick, United States P141 Nicholas Johnson IN SITU DEMONSTRATION OF RIFT VALLEY FEVER DISSEMINATION WITHIN CULEX PIPIENS MOSQUITOES Animal and Plant Health Agency, Addlestone, United Kingdom P142 Paul Brown EUROPEAN SUBGROUP C AVIAN METAPNEUMOVIRUS: PRELIMINARY EXPERIMENTAL INVESTIGATIONS ON THE ROLE OF THE SH PROTEIN IN PATHOGENICITY FOR MUSCOVY DUCKS ANSES, Ploufragan, France P143 Soner Yildiz INFLUENZA A VIRUS INFECTION PROMOTES LOCAL AND SYSTEMIC SUPER-INFECTION BY WEAKENING THE NATURAL SHIELD OF COMMENSAL BACTERIA UNIVERSITY OF GENEVA, CMU, Geneva, Switzerland P144 Takeaki Imamura AMINO ACID SUBSTITUTIONS IN THE PB2 PROTEIN OF AN H5N1 AVIAN INFLUENZA VIRUS ENHANCE ITS REPLICATION EFFICIENCY AND PATHOGENICITY IN MAMMALIAN HOSTS. THE INSTITUTE O MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan P145 Léa Meyer LOW-PATHOGENIC AVIAN INFLUENZA VIRUSES HIJACK HOST’S CENTRAL METABOLIC PATHWAYS INRA, Jouy-en-Josas, France P146 Monika Rottstegge A DONOR-MATCHED HUMANIZED MOUSE MODEL REVEALS A CHIEF ROLE OF THE APC- T CELL INTERFACE IN EBOLA VIRUS DISEASE Bernhard-Nocht-Institute, Hamburg, Germany P147 Julia Port LYMPHOCYTE HOMING SIGNATURES IN ACUTE LASSA VIRUS INFECTION Berhard Nocht Institut, Hamburg, Germany P148 Anne-Marie Connolly-Andersen MMP9 ASSOCIATES WITH ENDOTHELIAL GLYCOCALYX DEGRADATION DURING HEMORRHAGIC FEVER WITH RENAL SYNDROME UMEÅ UNIVERSITY, Umeå, Sweden PP149 Amelina Andrea Albornoz HANTAVIRUS RECEPTORS EXPRESSION AND DISTRIBUTION IN A LETHAL PULMONARY SYNDROME ANIMAL MODEL FUNDACIÓN CIENCIA Y VIDA, Santiago, Chile P150 Romy Kerber BIOMARKER ANALYSIS OF HUMAN EBOLA VIRUS DISEASE UNDERSCORES THE ROLE OF TISSUE INTEGRITY IN SURVIVAL BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany P151 Misa Korva CYTOKINE RESPONSE IN BUNYAVIRUS HEMORRHAGIC FEVERS UNIVERSITY OF LJUBLJANA, FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, Ljubljana, Slovenia P152 C Chevalier MOLECULAR CHARACTERIZATION OF PB1-F2-MEDIATED PATHOLOGY IN INFLUENZA MOUSE MODEL OF INFECTION INRA, Jouy-en-Josas, France P153 Linda Rennick RECOMBINANT GENOTYPE G MUMPS VIRUS EXPRESSING ENHANCED GREEN FLUORESCENT PROTEIN EFFICIENTLY REPLICATES IN PRIMARY HUMAN CELLS AND IS VIRULENT IN COTTON RATS BOSTON UNIVERSITY, Boston, United States P154 Pascale Massin THE HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1 A/CHICKEN/FRANCE/150169A/2015 PRESENTS IN VITRO PROPAGATION CHARACTERISTICS CONSISTENT WITH ITS PREDICTED TROPISM FOR AVIAN SPECIES ANSES, Ploufragan, France P155 Patrick Slaine ADAPTIVE MUTATIONS IN INFLUENZA A/CALIFORNIA/07/2009 ENHANCE POLYMERASE ACTIVITY AND INFECTIOUS VIRION PRODUCTION DALHOUSIE UNIVERSITY, Ridgeville, Canada P156 Luca Zaeck 3D IMAGING OF VIRUS INFECTIONS IN SOLVENT-CLEARED ORGANS FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany P157 Brigitta M Laksono HUMAN B-CELLS ARE HIGHLY SUSCEPTIBLE TO IN VITRO AND IN VIVO MEASLES VIRUS INFECTION ERASMUS MC, Rotterdam, Netherlands P158 Muneeswaran Selvaraj USE OF REVERSE GENETICS TECHNIQUE TO STUDY THE EARLY PATHOGENESIS OF PESTE DES PETITS RUMINANTS VIRUS THE PIRBRIGHT INSTITUTE, Woking, United Kingdom P159 Helena Müller ENTRY AND RELEASE OF LASSA VIRUS IN WELL-DIFFERENTIATED PRIMARY BRONCHIAL EPITHELIAL CELLS PHILIPPS UNIVERSITY MARBURG, Marburg, Germany

FIGHTING AND RESPONDING

P160 Zachary Bornholdt THE PAN-EBOLAVIRUS THERAPEUTIC COCKTAIL MBP134 DEMONSTRATES UNIVERSAL PROTECTION FROM PATHOGENIC EBOLAVIRUSES. MAPP BIOPHARMACEUTICAL, INC., San Diego, United States P161 Connie Schmaljohn ENHANCEMENT OF DNA VACCINES FOR EBOLA VIRUS WITH AN IMPROVED PLASMID DESIGN USAMRIID, Frederick, United States P162 Takeshi Ichinohe THE EFFECTS OF OUTSIDE TEMPERATURE IN THE INDUCTION OF ADAPTIVE IMMUNITY TO INFLUENZA VIRUS INFECTION UNIVERSITY OF TOKYO, Tokyo, Japan P163 Withdrawn P164 L Gubareva INSIGHTS INTO ANTIGENICITY OF INFLUENZA A(H3N2) VIRUS, 2012-2018 CDC, Atlanta, United States P165 Thomas Hoenen IDENTIFICATION OF ESSENTIAL HOST FACTORS FOR EBOLA VIRUS RNA SYNTHESIS USING A GENOME-WIDE siRNA SCREEN FRIEDRICH-LOEFFLER-INSTITUT, Greifswald, Germany P166 Irina Leneva CHARACTERIZATION OF INFLUENZA VIRUS CLINICAL ISOLATES OBTAINED DURING UMIFENOVIR CLINICAL STUDY “ARBITR” FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION I.MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA, Moscow, Russian Federation P167 Allison Groseth DEVELOPMENT AND APPLICATION OF ARENAVIRUS LIFECYCLE MODELLING SYSTEMS FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany P168 Hui-Wen Chen VACUOLAR ATPASE INHIBITING NANOPARTICLES EXHIBIT POTENT HOST-TARGETED ANTIVIRAL ACTIVITY AGAINST INFLUENZA VIRUSES National Taiwan University, Taipei, Taiwan P169 Christopher Donald Richardson A VSV-MEASLES CHIMERIC VIRUS CAN TARGET NECTIN-4 POSITIVE BREAST CANCER TUMORS IN AN IMMUNE COMPETENT MOUSE AND IS ENHANCED BY TRANSIENT INHIBITION OF ANTI-VIRAL INNATE IMMUNITY DALHOUSIE UNIVERSITY, Halifax, Canada P170 Michael Teng ENHANCING THE IMMUNOGENICITY AND ATTENUATION OF RESPIRATORY SYNCYTIAL VIRUS VACCINE CANDIDATES BY ALTERING NS1 FUNCTION UNIVERSITY OF SOUTH FLORIDA, Tampa, United States P171 David Hawman FAVIPIRAVIR BUT NOT RIBAVIRIN IS EFFECTIVE AGAINST TWO STRAINS OF CRIMEAN CONGO HEMORRHAGIC FEVER IN MICE NIH/NIAD, Hamilton, United States P172 Markus Kainulainen SCALABLE REPLICON-PARTICLE VACCINE PROTECTS AGAINST LETHAL LASSA VIRUS INFECTION IN THE GUINEA PIG MODEL Centers for Disease Control and Prevention, Atlanta, United States P173 Annelies Leemans REMOVAL OF THE N-GLYCOSYLATION SEQUON AT POSITION N116 LOCATED IN P27 OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN ELICITS ENHANCED ANTIBODY RESPONSES AFTER DNA IMMUNIZATION UNIVERSITY OF ANTWERP, Wilrijk, Belgium P174 Nicole Espy RIBAVIRIN HAS A DEMONSTRABLE EFFECT ON CRIMEAN-CONGO HEMORRHAGIC FEVER VIRAL POPULATIONS AND VIRAL LOAD DURING PATIENT TREATMENT UNITED STATES ARMY RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States P175 Victor Outlaw DEVELOPMENT OF BROAD-SPECTRUM PEPTIDOMIMETIC INHIBITORS OF PARAMYXOVIRAL FUSION UNIVERSITY OF WISCONSIN–MADISON, Madison, United States P176 Alexandra Kupke CORRELATES OF PROTECTION OF A MVA-BASED VACCINE AGAINST EBOLA VIRUS IN A MOUSE MODEL Institute of Virology, Philipps University Marburg, Marburg, Germany P177 Tomoko Kuwahara ISOLATION OF EGG-ADAPTED INFLUENZA A(H3N2) VIRUS WITHOUT AMINO ACID SUBSTITUTIONS IN THE ANTIGENIC SITES OF ITS HEMAGGLUTININ National Institute of Infectious Diseases, Musashi-Murayama, Japan P178 Felix Kreher BEWARE OF THE STING: THE SUPERPOWER OF MOSQUITO-PRODUCED RIFT VALLEY FEVER VIRUS GLASGOW UNIVERSITY, Glasgow, United Kingdom P179 Sarah Hulsey Stubbs A VESICULAR STOMATITIS VIRUS RECOMBINANT EXPRESSING THE OROPOUCHE VIRUS GLYCOPROTEINS ELICITS A NEUTRALIZING ANTIBODY RESPONSE IN MICE. HARVARD MEDICAL SCHOOL, Boston, United States P180 Emi Takashita IN VITRO CHARACTERIZATION OF MULTIDRUG-RESISTANT INFLUENZA A(H1N1)PDM09 VIRUSES CARRYING A DUAL AMINO ACID SUBSTITUTION ASSOCIATED WITH REDUCED SUSCEPTIBILITY TO NEURAMINIDASE INHIBITORS NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Tokyo, Japan P181 Mathieu Mateo ONE-SHOT IMMUNIZATION USING A MEASLES/LASSA VACCINE FULLY PROTECTS CYNOMOLGUS MONKEYS AGAINST LASSA FEVER INSTITUT PASTEUR, LYON, France P182 Sylvia Rothenberger IDENTIFICATION OF SMALL-MOLECULE VIRAL INHIBITORS TARGETING VARIOUS STAGES OF THE LIFE-CYCLE OF HANTAVIRUSES CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) AND UNIVERSITY OF LAUSANNE, Epalinges, Switzerland P183 Xavier Carnec A VACCINE PLATFORM AGAINST ARENAVIRUSES BASED ON A RECOMBINANT HYPER- ATTENUATED MOPEIA VIRUS EXPRESSING HETEROLOGOUS GLYCOPROTEINS Institut Pasteur, Lyon, France P184 Rashid Manzoor MECHANISM OF ANTIVIRAL ACTIVITY OF AN M2 ECTODOMAIN-SPECIFIC MONOCLONAL ANTIBODY AGAINST INFLUENZA A VIRUS RESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan P185 Cyril Le Nouen OPTIMIZATION OF THE CODON PAIR USAGE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS INCREASES PROTEIN SYNTHESIS BUT PARADOXICALLY DECREASES IMMUNOGENICITY NIH/NIAID/LID, BETHESDA, United States P186 Sameer Ayaz DEFECTIVE INTERFERING vRNA ARE PRESENT IN LIVE ATTENUATED INFLUENZA VACCINE BUT THEY ARE NOT A MAJORITY POPULATION AND DO NOT APPEAR TO DRIVE REDUCED VACCINE EFFECTIVENESS. ASTRAZENECA, Liverpool, United Kingdom P187 Lauren Parker HA STABILITY IS NOT THE SOLE DETERMINANT OF LIVE ATTENUATED INFLUENZA VACCINE EFFECTIVENESS MEDIMMUNE/ASTRAZENECA, Liverpool, United Kingdom P188 Nicolas Escriou LIVE RECOMBINANT MEASLES-M2 VACCINE CANDIDATES INDUCE BROAD- SPECTRUM PROTECTIVE IMMUNITY AGAINST INFLUENZA VIRUSES, INSTITUT PASTEUR, Paris, France P189 Roland Zahn THE ADENOVIRAL VECTOR AD26 EXPRESSING THE PREFUSION F PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS SHOWS HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE IN PRECLINICAL MODELS AS A PREREQUISITE FOR VACCINE DEVELOPMENT FOR YOUNG INFANTS Janssen Vaccines & Prevention, Leiden, Netherlands P190 Aaron Gingerich HYPOTHIOCYANITE DECREASES INFECTIVITY OF INFLUENZA A AND B VIRUSES INDEPENDENT OF NEURAMINIDASE ACTIVITY SUGGESTING A NOVEL MECHANISM OF VIRAL INACTIVATION UNIVERSITY OF GEORGIA, Athens, United States P191 Elizabeth Allen MOLECULAR BASIS OF ANTIBODY-MEDIATED NEUTRALIZATION REVEALS AN IMMUNODOMINANT SITE OF VULNERABILITY ON THE PHLEBOVIRAL SURFACE DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom P192 Maria Cristina Huertas-Diaz RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES BASED ON PARAINFLUENZA VIRUS 5 (PIV5) AMPLIFYING VIRUS-LIKE PARTICLES PROTECT MICE AGAINST RSV CHALLENGE UNIVERSITY OF GEORGIA, Athens, United States P193 Liang Ye IFN-LAMBDA ACTS AS MUCOSAL ADJUVANT STRONGLY PROMOTING TSLP- MEDIATED IgG1 AND IgA ANTIBODY RESPONSES INSTITUTE OF VIROLOGY, UNIVERSITY MEDICAL CENTER FREIBURG, Freiburg, Germany P194 Dorien De Vlieger BISPECIFIC FC GAMMA RECEPTOR ENGAGING MOLECULES PROTECT AGAINST INFLUENZA A VIRUS INFECTIONS VIB-UGhent Center for Medical Biotechnology, Ghent, Belgium P195 Anzhong Li A NOVEL METHYLTRANSFERASE-DEFECTIVE RECOMBINANT VESICULAR STOMATITIS VIRUS-BASED ZIKA VIRUS VACCINE EXPRESSING PRE-MEMBRANE, ENVELOPE AND NS1 PROTEIN THE OHIO STATE UNIVERSITY, Columbus, United States P196 Prerna Arora IDENTIFICATION OF DETERMINANTS THAT CONTROL ANTIVIRAL ACTIVITY OF DEFECTIVE INTERFERING PARTICLES (DIP) AND GENERATION OF TOOLS FOR DIP PRODUCTIONDEUTSCHES PRIMATENZENTRUM GMBH LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, GOETTINGEN, Germany P197 Peter Luc Delputte RESPIRATORY SYNCYTIAL VIRUS (RSV) ENTRY IS INHIBITED BY SERINE PROTEASE INHIBITOR AEBSF WHEN PRESENT DURING EARLY STAGE INFECTION UNIVERSITY OF ANTWERP, Antwerpen, Belgium P198 Sandra Diederich HENIPAVIRUS-LIKE PARTICLES INDUCE BOTH HUMORAL AND CELL-MEDIATED IMMUNE RESPONSE IN PIGS FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany P199 Ronan Nicolas Rouxel UNIVERSAL INFLUENZA VIRUS VACCINE: TWO DOSES OF ADJUVANTED CHIMERIC HEMAGGLUTININ INDUCE A STALK-SPECIFIC PROTECTIVE ANTIBODY RESPONSE AGAINST INFLUENZA VIRUS IN PRIMED ANIMALS GSK, Rixensart, Belgium P200 Dirk Roymans THERAPEUTIC EFFICACY OF A RESPIRATORY SYNCYTIAL VIRUS FUSION INHIBITOR Janssen Infectious Diseases, Beerse, Belgium P201 Yaiza Fernández García INCLUSION OF ANDES VIRUS CAP-SNATCHING ENDONUCLEASE IN THE SEARCH FOR NOVEL ANTIVIRALS BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany P202 Kore Schlottau ANTIVIRAL ACTIVITY OF RIBAVIRIN AND FAVIPIRAVIR AGAINST VARIEGATED SQUIRREL BORNAVIRUS 1 FRIEDRICH-LOEFFLER-INSTITUT, Greifswald – Riems, Germany P203 Ruth Watkinson DEVELOPMENT OF A TEMPERATURE SENSITIVE, INTERFERON-SILENT SENDAI VIRUS FOR DELIVERY OF CRISPR/CAS9 FOR HIGHLY EFFICIENT GENE EDITING IN HEMATOPOIETIC STEM CELLS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States P204 James Kelly CREATION OF A HIGH THROUGHPUT FUSION ASSAY TO SCREEN RSV INHIBITORS THE PIRBRIGHT INSTITUTE, Woking, United Kingdom P205 Stefanie A Krumm ELICITATION OF NEUTRALIZING ANTIBODIES AGAINST RVFV USING A RECOMBINANT Gn GLYCOPROTEIN. KING'S COLLEGE LONDON, London, United Kingdom P206 Stéphanie Anchisi HDAC6, A NOVEL HOST TARGET FOR BROAD SPECTRUM ANTIVIRAL THERAPY Faculty of medicine, University of Geneva, Genève, Switzerland P207 Svetlana Shcherbik ANALYSIS OF STABILITY OF LAIV REASSORTANTS BASED ON A/LENINGRAD/134/17/57 CDC/NCRID, Atlanta, United States P208 Hitoshi Takahashi ESTABLISHMENT OF THE CROSS-CLADE ANTIGEN DETECTION SYSTEM FOR H5 SUBTYPE INFLUENZA VIRUSES USING PEPTIDE MONOCLONAL ANTIBODIES SPECIFIC FOR INFLUENZA VIRUS H5 HEMAGGLUTININ NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan P209 Reiko Yoshida ANTIVIRAL EFFECTS OF MONOCLONAL ANTIBODIES TARGETING H5N1 INFLUENZA VIRUS HEMAGGLUTININ HOKKAIDO UNIVERSITY, Sapporo, Japan P210 Punya Ranjan STATINS SUPPRESS EBOLA VIRUS INFECTIVITY BY INTERFERING WITH GLYCOPROTEIN PROCESSING CENTER FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P211 Misako Yoneda IMMUNE INDUCTABILITY OF RECOMBINANT MEASLES VIRUS VACCINES AGAINS NIPAH VIRUS INFECTION. THE UNIVERSITY OF TOKYO, Tokyo, Japan P212 Oscar Negrete CRISPR SCREENS TARGETING VIRAL AND HOST GENOMES FOR ANTI-VIRAL COUNTERMEASURE DEVELOPMENT SANDIA NATIONAL LABORATORIES, Livermore, United States P213 Sibylle Haid LABYRINTHOPEPTIN A1 AND A2 EFFICIENTLY INHIBIT CELL ENTRY OF HUMAN RESPIRATORY SYNCYTIAL VIRUS IN VITRO AND IN VIVO TWINCORE-CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany P214 J. Maximilian Fels NEUTRALIZING ANTIBODIES AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS DERIVED FROM A HUMAN SURVIVOR ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States P215 Yasunori Watanabe STRUCTURE OF LASSA VIRUS GLYCAN SHIELD PROVIDES A MODEL FOR IMMUNOLOGICAL RESISTANCE UNIVERSITY OF SOUTHAMPTON, Oxford, United Kingdom P216 Miaoge Xue RATIONAL DESIGN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS LIVE ATTENUATED VACCINES BY INHIBITING VIRAL mRNA CAP METHYLTRANSFERASES THE OHIO STATE UNIVERSITY, Columbus, United States P217 Manon Laporte INHIBITION OF INFLUENZA- AND CORONAVIRUSES BY 1,4,4- TRISUBSTITUTED PIPERIDINES KU Leuven, Leuven, Belgium P218 Victoria Avanzato FLEXIBLE BAT IgG Fc QUATERNARY STRUCTURE PRESENTS ORDERED AND UNDER- PROCESSED GLYCANS University of Oxford, Oxford, United Kingdom

EMERGING AND EVOLVING

P219 Danielle Anderson COMPARATIVE LOSS-OF-FUNCTION SCREENS HIGHLIGHT COMMON CELLULAR PATHWAYS REQUIRED BY MUMPS VIRUS FOR REPLICATION IN BATS AND HUMANS DUKE-NUS MEDICAL SCHOOL, Singapore, Singapore P220 Hong Jin MOLECULAR ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) F AND G PROTEINS DURING THE 2015-2017 WINTER SEASONS IN THE US AND VIRAL SUSCEPTIBILITY TO ANTI-RSV MABS MEDIMMUNE, South San Francisco, United States P221 Mifang Liang EPIDEMIOLOGICAL INVESTIGATION AND MOLECULAR EVOLUTION OF SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME NATIONAL INSTITUTE FOR VIRAL DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China P222 Bertus Rima STRANGE STABLE REPLICATORS GENERATED FROM MUMPS VIRUS CDNA CLONES. QUEEN'S UNIVERSITY BELFAST, Belfast, United Kingdom P223 Randal Schoepp EVIDENCE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IN MONGOLIA USAMRIID, Fort Detrick, United States P224 Tony Schountz TRANSMISSION OF RESCUED BAT HL18NL11 INFLUENZA A-LIKE VIRUS IN EXPERIMENTALLY-INFECTED JAMAICAN FRUIT BATS COLORADO STATE UNIVERSITY, Fort Collins, United States P225 Samantha Kasloff PATHOGENICITY OF NIPAH VIRUS BANGLADESH IN EXPERIMENTALLY INFECTED PIGS Canadian Food Inspection Agency, National Centre for Foreign Animal Disease, WINNIPEG, Canada P226 Yasuha Arai GENETIC COMPATIBILITY AND VIRULENCE OF REASSORTANTS DERIVED FROM H9N2 AND H5N1 AVIAN INFLUENZA VIRUSES CO-CIRCULATING IN EGYPT KYOTO PREFECTURAL SCHOOL OF MEDICINE, Kyotoーshi, Japan P227 Won-Keun Kim MULTIPLEX PCR-BASED NEXT-GENERATION SEQUENCING OF HANTAVIRUSES IN HUMANS AND RODENTS KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of P228 Carles Martínez-Romero PHENOTYPIC EVOLUTION OF NEURAMINIDASE OF INFLUENZA A(H1N1)PDM09 VIRUS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States P229 Julia Dina IDENTIFICATION OF MUTATIONS IN GENES CODING FOR SURFACE F AND G PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS ISOLATED FROM CHILDREN TREATED WITH PALIVIZUMAB UNIVERSITY HOSPITAL OF CAEN, Caen, France P230 Jens Kuhn MEGATAXONOMY OF NEGATIVE-SENSE RNA VIRUSES: PHYLUM "NEGARNAVIRICOTA" NIH/NIAID/DCR/INTEGRATED RESEARCH FACILITY AT FORT DETRICK, Frederick, United States P231 Melle Holwerda ANALYSIS OF THE ZOONOTIC POTENTIAL OF INFLUENZA D VIRUS FOR HUMANS Institute for Virology and Immunology IVI, Bern, Switzerland P232 Helene Schulz BAYESIAN EVOLUTIONARY ANALYSIS BY SAMPLING TREES APPLIED TO EXTENDED SEQUENCING OF MEASLES VIRUS FOR MOLECULAR EPIDEMIOLOGY OF OUTBREAKS. PUBLIC HEALTH AGENCY OF CANADA, Winnipeg, Canada P233 Mifang Liang SEROLOGICAL INVESTIGATIONS OF LABORATORY-CONFIRMED AND SUSPECTED EBOLA PATIENTS DURING THE LATE PHASE OF THE EBOLA OUTBREAK IN SIERRA LEONE NATIONAL INSTITUTE FOR VIRAL DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China P234 Gvantsa Chanturia DETECTION OF HANTAVIRUS RNA IN HUMAN SAMPLES IN GEORGIA NATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH OF GEORGIA (NCDC), Tbilisi, Georgia P235 Suxiang Tong GENOMIC CHARACTERIZATION OF VIRUSES IN DROMEDARY CAMELS FROM UNITED ARAB EMIRATES CDC, Atlanta, United States P236 Rainer G. Ulrich MOLECULAR DETECTION OF PUUMALA ORTHOHANTAVIRUS: STRUGGLING WITH HIGH NUCLEOTIDE SEQUENCE VARIABILITY FRIEDRICH-LOEFFLER-INSTITUT, Greifswald-Insel Riems, Germany P237 Masayuki Horie SYSTEMATIC INVESTIGATION OF NOVEL LINEAGES OF ENDOGENOUS BORNAVIRUS- LIKE ELEMENTS IN VERTEBRATE GENOMES KYOTO UNIVERSITY, Kyoto, Japan P238 Laura Behner FUNCTIONAL KUMASI VIRUS SURFACE GLYCOPROTEIN G IS EXPRESSED IN HIGH- ORDER OLIGOMERS PHILIPPS UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany P239 Kerstin Fischer SEROLOGICAL EVIDENCE FOR THE CIRCULATION OF EBOLAVIRUSES IN SWINE IN WEST AFRICAFRIEDRICH-LOEFFLER-INSTITUT; INSTITUTE OF NOVEL AND EMERGING INFECTIOUS DISEASES Greifswald - Insel Riems, Germany P240 Masahiro Kajihara SEROLOGICAL AND MOLECULAR EVIDENCE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS CIRCULATION IN TICKS, CATTLE, AND HUMANS IN ZAMBIA HOKKAIDO UNIVERSITY, Sapporo, Japan P241 U.G. Liebert REVERSE GENETICS PLATFORM FOR IMPROVED CLONING AND EFFICIENT RESCUE OF MEASLES VIRUS FROM CDNA LEIPZIG UNIVERSITY, Leipzig, Germany P242 Naganori Nao THE CHARACTERISTICS OF RECENT CLINICAL ISOLATES OF HUMAN METAPNEUMOVIRUS IN JAPAN NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama city, Tokyo, Japan P243 Roena Sukhiashvili IDENTIFICATION OF NEW ENDEMIC REGION FOR CCHFV IN GEORGIA NATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH (NCDC), Tbilisi, Georgia P244 Yohei Watanabe CHARACTERIZATION OF H5N1 AVIAN INFLUENZA VIRUS QUASISPECIES WITH ADAPTIVE HEMAGGLUTININ MUTATIONS FROM SINGLE-VIRUS INFECTIONS OF HUMAN AIRWAY CELLS KYOTO PREFECTURAL UNIVERSITY OF MEDICINE, Kyoto, Japan P245 Bo Shu DEVELOPMENT AND QUALIFICATION OF REAL-TIME RT-PCR ASSAYS FOR THE DETECTION AND DISCRIMINATION OF INFLUENZA B VICTORIA LINEAGE K162N163 DELETION VIRUSES CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P246 Kai-Hui Wu PERFORMANCE EVALUATION OF THE UPDATED CDC REAL-TIME RT-PCR INFLUENZA B LINEAGE GENOTYPING PANEL CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States P247 Yohei Kurosaki DIFFERENT EFFECTS OF TWO MUTATIONS ON THE INFECTIVITY OF EBOLA VIRUS GLYCOPROTEIN IN NINE MAMMALIAN SPECIES INSTITUTE OF TROPICAL MEDICINE, NAGASAKI UNIVERSITY, Nagasaki, Japan P248 Alice Stelfox STRUCTURAL BASIS FOR DIVERGENT RECEPTOR TROPISM OF EMERGING UNCLASSIFIED PARAMYXOVIRUSES UNIVERSITY OF OXFORD, Oxford, United Kingdom P249 Noémie Aurine SOMATIC REPROGRAMMING IN PTEROPUS BAT CELLS TO DEVELOP NEW MODEL TO STUDY HIGHLY PATHOGENIC VIRUSES INSERM, Villeurbanne, France List of Participants

ABOU HAMDAN Abbas, CNRS, Gif Sur Yvettes, ANDREJEVA Jelena, UNIVERSITY OF ST. France - P013 ANDREWS, SCOTLAND, UK, St. Andrews, United [email protected] Kingdom - P072 [email protected] AGUILAR-CARRENO Hector, CORNELL UNIVERSITY, Ithaca, United States - 8 ANTHONY Simon, COLUMBIA UNIVERSITY, NYC, [email protected] United States [email protected] AIT-GOUGHOULTE Malika, ROCHE, Basel, Switzerland ARAI Yasuha, KYOTO PREFECTURAL SCHOOL OF [email protected] MEDICINE, Kyotoーshi, Japan - P226 [email protected] ALARCÓN Rodolfo, Bethesda, United States - [email protected] ARNOLD Catherine, U.S ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, ALBERTINI Aurelie, CNRS, Gif Sur Yvette, France Frederick, United States - P070 - 4, P013 [email protected] [email protected] ARORA Prerna, DEUTSCHES ALBORNOZ Amelina, FUNDACIÓN CIENCIA Y PRIMATENZENTRUM GMBH LEIBNIZ-INSTITUT VIDA, Santiago, Chile - P149 FÜR PRIMATENFORSCHUNG, Goettingen, [email protected] Germany - P196 [email protected] ALLEN Elizabeth, DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, AURINE Noémie, Villeurbanne, France - 88, United Kingdom - P191, P205 P249 [email protected] [email protected]

AMARASINGHE Gaya, WASHINGTON AVANZATO Victoria, UNIVERSITY OF OXFORD, UNIVERSITY SCHOOL OF MEDICINE, St. Louis, Oxford, United Kingdom - P218 United States - 50, P030 [email protected] [email protected] AVENA Laura, San Antonio, United States - ANCHISI Stéphanie, FACULTY OF MEDICINE, [email protected] UNIVERSITY OF GENEVA, Genève, Switzerland - P206 AVSIC ZUPANC Tatjana, UNIVERSITY OF [email protected] LJUBLJANA, FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, ANDERSON Danielle, DUKE-NUS MEDICAL Ljubljana, Slovenia - P150, P151 SCHOOL, Singapore, Singapore - 69, P219 [email protected] [email protected] AYAZ Sameer, ASTRAZENECA, Liverpool, United BECKER Stephan, INSTITUT FÜR VIROLOGIE, Kingdom - P186 PHILIPPS-UNIVERSITÄT MARBURG, Marburg, [email protected] Germany - P193 [email protected] AZARM Kristopher, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United BEHNER Laura, PHILIPPS UNIVERSITY MARBURG, States - P009, P021 INSTITUTE OF VIROLOGY, Marburg, Germany - [email protected] P065, P110, P238 [email protected] BACH Simone, PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany - 18 BELOT Laura, I2BC, Gif-Sur-Yvette, France - 4, [email protected] P013 [email protected] BADHAM Matthew, UNIVERSITY OF KENT, Canterbury, United Kingdom - P116 BENTON Donald, THE FRANCIS CRICK INSTITUTE, [email protected] London, United Kingdom - 3 [email protected] BAILEY Dalan, THE PIRBRIGHT INSTITUTE, Guildford, United Kingdom - P003, P173, P204 BERTRAN Andre, LABORATORY OF VIROLOGY, [email protected] WAGENINGEN UNIVERSITY, Wageningen, Netherlands - P046 BAILLET Nicolas, Lyon, France - P181 [email protected] [email protected] BEURET Christian, SPIEZ LABORATORY, Spiez, BAILLON Laury, INRA, Jouy En Josas, France - 28 Switzerland [email protected] [email protected]

BAIZE Sylvain, INSTITUT PASTEUR, Lyon Cedex 7, BIACCHESI Stephane, INRA, Jouy En Josas, France - P138, P181, P183 France - 28 [email protected] [email protected]

BAKKERS Mark, HARVARD MEDICAL SCHOOL, BIEDENKOPF Nadine, PHILIPPS-UNIVERSITÄT Boston, United States - P016 MARBURG, Marburg, Germany - 18, P036, P047 [email protected] [email protected]

BARCLAY Wendy, IMPERIAL COLLEGE, London, BLOYET Louis-Marie, HARVARD MEDICAL United Kingdom - 20, 71, P091 SCHOOL, Boston, United States - 24, 88, P038, [email protected] P058 [email protected] BASLER Christopher, GEORGIA STATE UNIVERSITY, Atlanta, United States - 17, P073 BOGDANOW Boris, MDC BERLIN, Berlin, [email protected] Germany - P059 [email protected] BAUER David, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 66, P056, P066, P115 BOON Jacco, WASHINGTON UNIVERSITY, Saint [email protected] Louis, United States - 19, 50 [email protected] BÖRGELING Yvonne, UNIVERSITY OF BRUNOTTE Linda, UNIVERSITY OF MUENSTER, MUENSTER, Münster, Germany - P111 Muenster, Germany - 35 [email protected] of [email protected]

BORNHOLDT Zachary, MAPP BUCHHOLZ Ulla, NIAID, NIH, Bethesda, United BIOPHARMACEUTICAL, INC., San Diego, United States - 79, 91, P185 States - P160, P214 [email protected] [email protected] BUKREYEV Alexander, UNIVERSITY OF TEXAS BOTTEN Jason, UNIVERSITY OF VERMONT, MEDICAL BRANCH AT GALVESTON, GALVESTON Burlington, United States - 47, 48, P112 NATIONAL LABORATORY, Galveston, United [email protected] States - 32 [email protected] BOURHIS Jean-Marie, INSTITUT DE BIOLOGIE STRUTURALE, Grenoble, France - P026 BYRD-LEOTIS Lauren, HARVARD MEDICAL [email protected] SCHOOL, Boston, United States - P004 [email protected] BOWDEN Thomas, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 10, 74, P009, P018, CALDER Lesley, THE FRANCIS CRICK INSTITUTE, P019, P021, P205, P191, P215, P218, P248 London, United Kingdom - 3 [email protected] [email protected]

BREMONT Michel, INRA, Jouy En Josas, France - CANTONI Diego, UNIVERSITY OF KENT, 28 Canterbury, United Kingdom - P081 [email protected] [email protected]

BRENNAN Benjamin, MRC-UNIVERSITY OF CARDONE Christophe, CNRS ICSN, Gif-Sur-Yvette GLASGOW CENTRE FOR VIRUS RESEARCH, Cedex, France - P027, P055 Glasgow, United Kingdom - P191 [email protected] [email protected] CARNEC Xavier, INSTITUT PASTEUR, Lyon, BROOKE Chris, UNIVERSITY OF ILLINOIS, Urbana, France - P181, P183 United States - 26 [email protected] [email protected] CARRIQUE Loic, UNIVERSITY OF OXFORD, BROWN Paul, ANSES, Ploufragan, France - P142 Oxford, United Kingdom [email protected] [email protected]

BRUCE Emily, UNIVERSITY OF VERMONT, CASHMAN Kathleen, THE GENEVA FOUNDATION Burlington, United States - 47 / USAMRIID, Fort Detrick, United States - P140 [email protected] [email protected]

BRUCHEZ Anna, BENAROYA RESEARCH CATTANEO Roberto, MAYO CLINIC, Rochester, INSTITUTE, Seattle, United States - P071 United States - 2, 25, P067 [email protected] [email protected] CHANDA Sumit, SANFORD BURNHAM PREBYS COURRIER Alexis, UNIGE, Geneva, Switzerland - MEDICAL DISCOVERY INSITUTE, La Jolla, United [email protected] States - P068, P069 [email protected] CREPIN Thibaut, IBS, UNIV. GRENOBLE ALPES, CEA, CNRS, Grenoble, France - P026 CHANDRAN Kartik, ALBERT EINSTEIN COLLEGE [email protected] OF MEDICINE, Bronx, United States - 5, 6, P006, P017, P160, P214 CUSI Maria Grazia, UNIVERSITY OF SIENA, Siena, [email protected] Italy - P092 [email protected] CHANTURIA Gvantsa, NATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH OF DADONAITE Bernadeta, UNIVERSITY OF GEORGIA (NCDC), Tbilisi, Georgia - P234, P243 OXFORD, Oxford, United Kingdom - P115 [email protected] [email protected]

CHEN Hui-Wen, NATIONAL TAIWAN UNIVERSITY, DE BOER Steffen Matthijn, INTRAVACC, Taipei, Taiwan - P168 Apeldoorn, Netherlands - [email protected] [email protected]

CHEVALIER Christophe, INRA, Jouy-En-Josas, DE SWART Rik, ERASMUS MC, Rotterdam, France - P152 Netherlands - 55, 60, P157 [email protected] [email protected]

CIMINSKI Kevin, UNIVERSITY MEDICAL CENTER DE VLIEGER Dorien, VIB-UGENT CENTER FOR FREIBURG CENTER FOR MICROBIOLOGY AND MEDICAL BIOTECHNOLOGY , VIB, GHENT, HYGIENE INSTITUTE OF VIROLOGY, Freiburg, BELGIUM, Zwijnaarde, Belgium - P194 Germany - 1, 90 [email protected] [email protected] DELMAS Bernard, INRA, Jouy-En-Josas, France - CLOHISEY Sara, THE ROSLIN INSTITUTE, P026, P040, P145, P152 Edinburgh, United Kingdom - P076 [email protected] [email protected] DELPUTTE Peter, UNIVERSITY OF ANTWERP, COMPANS Richard, EMORY UNIVERSITY, Antwerpen, Belgium - P173, P197 Atlanta, United States [email protected] [email protected] DENG Tao, INSTITUTE OF PATHOGEN CONCEICAO Carina, THE ROSLIN INSTITUTE, BIOLOGY,CHINESE ACADEMY OF MEDICAL UNIVERSITY OF EDINBURGH, Roslin, United SCIENCES, Beijing, China - P107 Kingdom - P117 [email protected] [email protected] DEVIGNOT Stéphanie, INSTITUTE FOR CONNOLLY-ANDERSEN Anne-Marie, UMEÅ VIROLOGY, FB10 VETERINARY MEDICINE, UNIVERSITY, Umeå, Sweden - P148 Giessen, Germany - P089 [email protected] [email protected]

CONZELMANN Karl-Klaus, LMU MUNICH, München, Germany - 27, P130 [email protected] DIBBEN Oliver, MEDIMMUNE, Liverpool, United EDWARDS Megan, GEORGIA STATE UNIVERSITY, Kingdom - 81, P186, P187 Atlanta, United States - P073 [email protected] of [email protected]

DIEDERICH Sandra, FRIEDRICH-LOEFFLER- ELEOUET Jean-Francois, INRA, Jouy En Josas, INSTITUT, Greifswald - Insel Riems, Germany - France - P027, P028, P039, P051, P055, P213 P198, P239 [email protected] [email protected] ESCRIOU Nicolas, INSTITUT PASTEUR, Paris, DIJKMAN Ronald, INSTITUTE OF VIROLOGY AND France - P188 IMMUNOLOGY IVI, Bern, Switzerland - 36, P061, [email protected] P213, P231 [email protected] ESPY Nicole, UNITED STATES ARMY RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, DINA Julia, UNIVERSITY HOSPITAL OF CAEN, United States - P174 Caen, France - P229 [email protected] [email protected] FALCON Ana, CENTER FO BIOMEDICAL DOLNIK Olga, PHILIPPS-UNIVERSITY MARBURG, RESEARCH (CIBER), Madrid, Spain - 33, 65 Marburg, Germany - P113 [email protected] [email protected] FAN Haitian, UNIVERSITY OF OXFORD, Oxford, DONOHUE Ryan, MAYO CLINIC, Rochester, United Kingdom - 14, P056 United States - 2, 25 [email protected] [email protected] FAY Elizabeth, UNIVERSITY OF MINNESOTA, DOORES Katie, KING'S COLLEGE LONDON, Minneapolis, United States - 42 London, United Kingdom - 74, P191, P205 [email protected] [email protected] FEARNS Rachel, BOSTON UNIVERSITY SCHOOL DUPREX Paul, BOSTON UNIVERSITY SCHOOL OF OF MEDICINE, Boston, United States - 22 MEDICINE, Boston, United States - 55, P049, [email protected] P153, P213, P219, P222 [email protected] FEDELI Chiara, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - 11 DUTCH Rebecca, UNIVERSITY OF KENTUCKY, [email protected] Lexington, United States - 7 [email protected] FEHLING Sarah, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P118, P159 EATON Brett, US ARMY MEDICAL RESEARCH [email protected] INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States FELS J. Maximilian, ALBERT EINSTEIN COLLEGE [email protected] OF MEDICINE, Bronx, United States - 6, P214 [email protected] FERNÁNDEZ GARCÍA Yaiza, BERNHARD NOCHT GAST Matthieu, UNIVERSITY OF BERN VETUISSE INSTITUTE FOR TROPICAL MEDICINE, Hamburg, FACULTY, Bern, Switzerland - P122, P123 Germany - P201 [email protected] [email protected] GAUDIN Yves, INSTITUT DE BIOLOGIE FIEGE Jessica, UNIVERSITY OF MINNESOTA, INTÉGRATIVE DE LA CELLULE, CNRS, Gif Sur Minneapolis, United States - 42, 58 Yvette, France - 4, 46, P013 [email protected] [email protected]

FINKE Stefan, FRIEDRICH-LOEFFLER-INSTITUT, GERLIER Denis, CIRI INSERM U1111, CNRS Greifswald - Insel Riems, Germany - 49, P121, UMR5307, UNIVERSITY LYON 1, ENS LYON, UNIV P156, P165 LYON, Lyon, France - 88, P038, P058 [email protected] [email protected]

FISCHER Kerstin, FRIEDRICH-LOEFFLER-INSTITUT; GHANEM Alexander, LMU MUNICH, Munich, INSTITUTE OF NOVEL AND EMERGING Germany - P130 INFECTIOUS DISEASES, Greifswald - Insel Riems, [email protected] Germany - P239 [email protected] GIAVEDONI Luis, TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States FODOR Ervin, UNIVERSITY OF OXFORD, Oxford, [email protected] United Kingdom - 14, 66, P023, P034, P056, P066, P115 GINGERICH Aaron, UNIVERSITY OF GEORGIA, [email protected] Athens, United States - P190 [email protected] FUJIYUKI Tomoko, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P124, P137 GOLDHILL Daniel, IMPERIAL COLLEGE, London, [email protected] United Kingdom - 71 [email protected] GAGLIA Marta, TUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, United States - 34 GOUJON Caroline, INSTITUT DE RECHERCHE EN [email protected] INFECTIOLOGIE DE MONTPELLIER (IRIM), CNRS / MONTPELLIER UNIVERSITY, Montpellier, France GALAO Rui, KING'S COLLEGE LONDON, London, - 37, P091 United Kingdom - 39, P075 [email protected] [email protected] GOULD Joseph, UNIVERSITY OF ALABAMA AT GANDOLFO Claudia, UNIVERSITY OF SIENA, Colle BIRMINGHAM, Birmingham, United States - Di Val D'Elsa, Italy - P092 P057 [email protected] [email protected]

GARCÍA-SASTRE Adolfo, ICAHN SCHOOL OF GOVORKOVA Elena, ST. JUDE CHILDREN'S MEDICINE AT MOUNT SINAI, New York, United RESEARCH HOSPITAL, Memphis, United States - States - 1, 19, 30, P068, P069, P108, P228 [email protected] [email protected] GREEN Todd, Birmingham, United States - P057 GARCIN Dominique, UNIVERSITY OF GENEVA, [email protected] Geneva, Switzerland - 56 [email protected] GRIFFIN Diane, JOHNS HOPKINS BLOOMBERG HARA Koyu, KURUME UNIVERSITY SCHOOL OF SCHOOL OF PUBLIC HEALTH, Hunt Valley, United MEDICINE, Kurume, Japan - P052 StatesList - 83 of [email protected] [email protected] HARMON Brooke, Livermore, United States - GRIFFITHS Anthony, TEXAS BIOMED, San P132, P172 Antonio, United States - 59, P054 [email protected] [email protected] HARTMAN Amy, UNIVERSITY OF PITTSBURGH, GROSETH Allison, FRIEDRICH-LOEFFLER- Pittsburgh, United States - 64, P125 INSTITUT, Greifswald - Insel Riems, Germany - [email protected] P165, P167 [email protected] HAWMAN David, NIH/NIAD, Hamilton, United States - P171 GUBAREVA Larisa, CDC, Atlanta, United States - [email protected] P164 [email protected] HENNRICH Alexandru Adrian, LMU MÜNCHEN, Munich, Germany - P130 GUITO Jonathan, CENTERS FOR DISEASE [email protected] CONTROL AND PREVENTION, Atlanta, United States - P070 HERREN Michael, UNIVERSITY OF BERN, Bern, [email protected] Switzerland - P011 [email protected] GÜNTHER Maria, FRIEDRICH-LOEFFLER- INSTITUT, Greifswald - Insel Riems, Germany - HERRLER Georg, STIFTUNG TIERÄRZTLICHE P121 HOCHSCHULE HANNOVER, Hannover, Germany - [email protected] P015, P064, P127 [email protected] HAID Sibylle, TWINCORE- CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION HERSCHKE Florence, JANSSEN PHARMACEUTICA RESEARCH, Hannover, Germany - 62, P020, P213 NV, Beerse, Belgium [email protected] [email protected]

HALE Benjamin, UNIVERSITY OF ZURICH, Zurich, HERZOG Norbert, FRANK H. NETTER SCHOOL OF Switzerland - 1 MEDICINE, Guilford, United States - [email protected] [email protected]

HALLER Otto, INSTITUTE OF VIROLOGY, MEDICAL HOENEN Thomas, FRIEDRICH-LOEFFLER- CENTER - UNIVERSITY OF FREIBURG, GERMANY, INSTITUT, Greifswald, Germany - P165, P167, Zürich, Switzerland P239 [email protected] [email protected]

HAN Julianna, THE UNIVERSITY OF CHICAGO, HOFFMANN Markus, DEUTSCHES Chicago, United States - P078 PRIMATENZENTRUM GMBH, LEIBNIZ-INSTITUT [email protected] FÜR PRIMATENFORSCHUNG, Göttingen, Germany - P093 [email protected] HOLWERDA Melle, INSTITUTE FOR VIROLOGY IMAMURA Takeaki, THE INSTITUTE O MEDICAL AND IMMUNOLOGY IVI, Bern, Switzerland - SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, P061, P231 Japan - P144 [email protected] [email protected]

HONDA Tomoyuki, OSAKA UNIVERISTY, Osaka, IRIE Takashi, HIROSHIMA UNIVERSITY, Japan - P098 Hiroshima, Japan - P120 [email protected] [email protected]

HOOPER Jay, Fort Detrick, United States - P149 JANGRA Rohit, ALBERT EINSTEIN COLLEGE OF [email protected] MEDICINE, Bronx, United States - 5, 6, P006, P017 HORIE Masayuki, KYOTO UNIVERSITY, Kyoto, [email protected] Japan - P044, P105, P237 [email protected] JIN Hong, MEDIMMUNE, South San Francisco, United States - P220 HORVAT Branka, CIRI, Lyon, France - 88, P249 [email protected] [email protected] JOHNSON Nicholas, ANIMAL AND PLANT HORWITZ Joshua, HARVARD MEDICAL SCHOOL, HEALTH AGENCY, Addlestone, United Kingdom - Boston, United States - P050 P141 [email protected] [email protected]

HUA Brian, CENTERS FOR DISEASE CONTROL JOHNSON Rebecca, CSIRO-AUSTRALIAN ANIMAL AND PREVENTION, Atlanta, United States - 40, HEALTH LABORATORY, East Geelong, Australia - P131 - [email protected] 86 [email protected] HUERTAS-DIAZ Maria, UNIVERSITY OF GEORGIA, Athens, United States - P192 JONSSON Colleen, UNIVERSITY OF TENNESSEE [email protected] HEALTH SCIENCE CENTER, Memphis, United States - P085 HULSEY STUBBS Sarah, HARVARD MEDICAL [email protected] SCHOOL, Boston, United States - P016, P179 [email protected] KADZIOCH Nicole, UNIVERSITY OF BERN, VETSUISSE FACULTY, Bern, Switzerland - P122, HUTCHINSON Edward, MRC-UNIVERSITY OF P123 GLASGOW CENTRE FOR VIRUS RESEARCH, [email protected] Glasgow, United Kingdom - 43, P023, P032 [email protected] KAI Chieko, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, P090, P096, P124, P137, P139, ICHINOHE Takeshi, UNIVERSITY OF TOKYO, P211 Tokyo, Japan - P080, P086, P162 [email protected] [email protected] KAINULAINEN Markus, CENTERS FOR DISEASE IKEDA Fusako, THE UNIVERSITY OF TOKYO, CONTROL AND PREVENTION, Atlanta, United Tokyo, Japan - P096, P139 States - P172 [email protected] [email protected] KAJIHARA Masahiro, HOKKAIDO UNIVERSITY, KOEHLER Alexander, PHILIPPS UNIVERSITY Sapporo, Japan - P240 MARBURG, Marburg, Germany - P045 [email protected] of [email protected]

KARAKUS Umut, UNIVERSITY OF ZURICH, KOHL Alain, MRC-UNIVERSITY OF GLASGOW INSTITUTE OF MEDICAL VIROLOGY, Zurich, CENTRE FOR VIRUS RESEARCH, Glasgow, United Switzerland - 1 Kingdom - P042, P178 [email protected] [email protected]

KASLOFF Samantha, CANADIAN FOOD KOJIMA Shohei, KYOTO UNIVERSITY, Kyoto, INSPECTION AGENCY, NATIONAL CENTRE FOR Japan - P044, P105, P237 FOREIGN ANIMAL DISEASE, Winnipeg, Canada - [email protected] P225 - [email protected] KOLAKOVSKY Daniel, Switzerland KATZ Aliza, WEIZMANN INSTITUTE, Jerusalem, [email protected] Israel – 82 - [email protected] KONDOH Tatsunari, DIVISION OF GLOBAL KAWAGUCHI Atsushi, UNIVERSITY OF TSUKUBA, EPIDEMIOLOGY, RESEARCH CENTER FOR Tsukuba, Japan - P060, P101 ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, [email protected] Sapporo, Japan - P010 [email protected] KELLY James, THE PIRBRIGHT INSTITUTE, Woking, United Kingdom - P204 KORMELINK Richard, WAGENINGEN [email protected] UNIVERSITY, Wageningen, Netherlands - P046 [email protected] KEOWN Jeremy, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 14 KORVA Misa, UNIVERSITY OF LJUBLJANA, [email protected] FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, Ljubljana, KERBER Romy, BERNHARD NOCHT INSTITUTE Slovenia - P150, P151 FOR TROPICAL MEDICINE, Hamburg, Germany - [email protected] P150 - [email protected] KOWALIK Timothy, UNIVERSITY OF KIM Jin II, MICROBIOLOGY, KOREA UNIVERSITY MASSACHUSETTS MEDICAL SCHOOL, Worcester, COLLEGE OF MEDICINE, Seoul, Korea, Republic United States Of - [email protected] [email protected]

KIM Won-Keun, KOREA UNIVERSITY COLLEGE OF KREHER Felix, GLASGOW UNIVERSITY, Glasgow, MEDICINE, Seoul, Korea, Republic Of - P227 United Kingdom - P178 [email protected] [email protected]

KLEINFELTER Lara, ALBERT EINSTEIN COLLEGE KRÜGER Nadine, UNIVERSITY OF VETERINARY OF MEDICINE, Bronx, United States - 6, P017 MEDICINE HANNOVER, Hannover, Germany - [email protected] P015, P065, P127 [email protected] KLINGSTROM Jonas, KAROLINSKA INSTITUTET, Stockholm, Sweden - 41, P037 [email protected] KRUMM Stefanie, KING'S COLLEGE LONDON, LAKSONO Brigitta, ERASMUS MC, Rotterdam, London, United Kingdom - 74, P191, P205 Netherlands - 60, P157 [email protected] [email protected]

KUHN Jens, NIH/NIAID/DCR/INTEGRATED LANGEDIJK Johannes, JANSSEN VACCINES AND RESEARCH FACILITY AT FORT DETRICK, Frederick, PREVENTION, Leiden, Netherlands - 75, P200 United States – 84, P230 [email protected] [email protected] LANGLOIS Ryan, UNIVERSITY OF MINNESOTA, KUMAR Gagandeep Renuka, CHAN Minneapolis, United States - 42, 58 ZUCKERBERG BIOHUB, San Francisco, United [email protected] States - [email protected] LAPORTE Manon, REGA INSTITUTE - KU LEUVEN, Leuven, Belgium - P014, P217 KUNZ Stefan, LAUSANNE UNIVERSITY HOSPITAL, [email protected] Lausanne, Switzerland - 11, 85, P007, P008, P182 LAU Simone, JUSTUS-LIEBIG UNIVERSITY, [email protected] Giessen, Germany - P103 [email protected] KUPKE Alexandra, INSTITUTE OF VIROLOGY, PHILIPPS UNIVERSITY MARBURG, Marburg, LE GOFFIC Ronan, INRA, Jouy-En-Josas, France - Germany - P176 P028, P040, P145, P152 [email protected] [email protected]

KUROSAKI Yohei, INSTITUTE OF TROPICAL LEE Benhur, ICAHN SCHOOL OF MEDICINE AT MEDICINE, NAGASAKI UNIVERSITY, Nagasaki, MOUNT SINAI, New York, United States - P009, Japan - P247 P021, P203 [email protected] [email protected]

KUTTER Jasmin, ERASMUS MEDICAL CENTER LEE Sangjoon, UNIVERSITY OF TSUKUBA, ROTTERDAM, Rotterdam, Netherlands Tsukuba, Japan - P060, P101 [email protected] [email protected]

KUWAHARA Tomoko, NATIONAL INSTITUTE OF LEEMANS Annelies, UNIVERSITY OF ANTWERP, INFECTIOUS DISEASES, Musashi-Murayama, Wilrijk, Belgium - P173, P197 Japan - P177, P180 [email protected] [email protected] LENEVA Irina, FEDERAL STATE BUDGETARY LACOUNT Douglas, PURDUE UNIVERSITY, West SCIENTIFIC INSTITUTION I.MECHNIKOV Lafayette, United States - P126 RESEARCH INSTITUTE FOR VACCINES AND SERA, [email protected] Moscow, Russian Federation - P166 [email protected] LAKDAWALA Seema, UNIVERSITY OF PITTSBURGH, Pittsburgh, United States - 52 LENOUEN Cyril, NIH/NIAID/LID, Bethesda, [email protected] United States - 91, P185 [email protected] LEUNG Daisy, WASHINGTON UNIVERSITY LUBAN Jeremy, UNIVERSITY OF SCHOOL OF MEDICINE, St. Louis, United States - MASSACHUSETTS MED SCHOOL, Worcester, 29 List of ParticipantsUnited States - P001 [email protected] [email protected]

LI Anzhong, THE OHIO STATE UNIVERSITY, LUO Ming, GEORGIA STATE UNIVERSITY, Atlanta, Columbus, United States - 16, P195 United States - P024, P043 [email protected] [email protected]

LI Jianrong, THE OHIO STATE UNIVERSITY, MAHAPATRA Madhuchhanda, THE PIRBRIGHT Columbus, United States - 16, P195, P216 INSTITUTE, Woking, United Kingdom - [email protected] [email protected]

LI Ping, Glasgow, United Kingdom MAISNER Andrea, PHILIPPS UNIVERSITY [email protected] MARBURG, Marburg, Germany - P065, P110, P198, P238 LIANG Bo, EMORY UNIVERSITY SCHOOL OF [email protected] MEDICINE, Atlanta, United States - P029 [email protected] MAKINO Akiko, KYOTO UNIVERSITY, Kyoto, Japan - 15, P105 LIANG Mifang, NATIONAL INSTITUTE FOR VIRAL [email protected] DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China - P221, P233 MANHART Whitney, BOSTON UNIVERSITY [email protected] SCHOOL OF MEDICINE, Boston, United States - P102 LIANG Xueya, DEPARTMENT OF VETERINARY [email protected] BIOSCIENCES, COLLEGE OF VETERINARY MEDICINE, THE OHIO STATE UNIVERSITY, Dublin, MANZOOR Rashid, RESEARCH CENTER FOR United States - 16, P195, P216 ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, [email protected] Sapporo, Japan - P010, P184, P209 [email protected] LIEBERT Uwe G., LEIPZIG UNIVERSITY, Leipzig, Germany - P241 MARTÍNEZ-ROMERO Carles, ICAHN SCHOOL OF [email protected] MEDICINE AT MOUNT SINAI, New York, United States - 30, P228 LIU Cheng, ALIOS BIOPHARMA, INC., PART OF [email protected] THE JANSSEN PHARMACEUTICAL COMPANIES, South San Francisco, United States - MARTIN-SANCHO Laura, SBP MEDICAL [email protected] DISCOVERY INSTITUTE, San Diego, United States - P068 LONG Jason, IMPERIAL COLLEGE LONDON, [email protected] London, United Kingdom - 20 [email protected] MASSIN Pascale, ANSES, Ploufragan, France - P154 LOWEN Anice, EMORY UNIVERSITY, Atlanta, [email protected] United States - 21, 89 [email protected] MATEO Mathieu, INSTITUT PASTEUR, Lyon, MEYER Léa, INRA, Jouy-En-Josas, France - P145 France - 2, P097, P181 [email protected] [email protected] MIRAZIMI Ali, PUBLIC HEALTH AGENCY OF MATHIEU Cyrille, COLUMBIA UNIVERSITY SWEDEN AND KAROLINSKA INSTITUTE, MEDICAL CENTER, New York, United States - 61, Stockholm, Sweden - P089 88 [email protected] [email protected] MITTLER Eva, ALBERT EINSTEIN COLLEGE OF MATSUMOTO Yusuke, SCHOOL OF MEDICINE, MEDICINE, New York, United States - 5, 6 WAKAYAMA MEDICAL UNIVERSITY, Wakayama, [email protected] Japan - P094, P095 [email protected] MIYAMOTO Sho, INSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES, KYOTO UNIVERSITY, MAYOR Jennifer, LAUSANNE UNIVERSITY Kyoto, Japan - P114 HOSPITAL, Lausanne, Switzerland - P007, P008, [email protected] P182 [email protected] MOMOSE Fumitaka, KITASATO UNIVERSITY, Minato-Ku, Japan - P119 MAZEL-SANCHEZ Béryl, UNIVERSITY OF GENEVA, [email protected] Geneva, Switzerland - 36, P143 [email protected] MONCORGÉ Olivier, IRIM, Montpellier, France - 37, P091 MAZUR Magdalena, LABORATORY OF [email protected] VIROLOGY, WAGENINGEN UNIVERSITY, Wageningen, Netherlands - P046 MORENO BORREGO Hector, LAUSANNE [email protected] UNIVERSITY HOSPITAL, Lausanne, Switzerland - 85 MCMULLAN Laura, CENTERS FOR DISEASE [email protected] CONTROL, Atlanta, United States - 40 [email protected] MORIYAMA Miyu, UNIVERSITY OF TOKYO, Tokyo, Japan - P080, P086, P162 MEDINA Rafael, PONTIFICIA UNIVERSIDAD [email protected] CATOLICA DE CHILE, Santiago, Chile - P108 [email protected] MOSCONA Anne, COLUMBIA UNIVERSITY MEDICAL CENTER, New York, United States - 61, MEHLE Andrew, UNIVERSITY OF WISCONSIN P175 MADISON, Madison, United States - 19 [email protected] [email protected] MOTTET-OSMAN Geneviève, UNIVERSITY OF MEROUR Emilie, Jouy En Josas, France - 28 GENEVA, Geneva 4, Switzerland [email protected] [email protected]

MERTZ Gregory, UNIVERSITY OF NEW MEXICO MOTTRAM Timothy, MRC-UNIVERSITY OF HEALTH SCIENCES CETNERR, Albuquerque, GLASGOW CENTRE FOR VIRUS RESEARCH, United States - Glasgow, United Kingdom - P042 [email protected] [email protected] MÜLLER Helena, PHILIPPS UNIVERSITY NISHIO Machiko, WAKAYAMA MEDICAL MARBURG, Marburg, Germany - P159 UNIVERSITY, Wakayama, Japan - P002, P094, [email protected] of -marburg.deParticipantsP095 [email protected] MUNIR Shirin, NATIONAL INSTITUTES OF HEALTH, Bethesda, United States - NODA Takeshi, KYOTO UNIVERSITY, Kyoto, Japan [email protected] - 45, P114 [email protected] MUNOZ ALIA Miguel Angel, MAYO CLIIC, Rochester, United States - 78 NOLDEN Tobias, VIRATHERAPEUTICS, Innsbruck, [email protected] Austria - 49 [email protected] MUNOZ-FONTELA César Munoz-Fontela, BERNHARD-NOCHT INSTITUTE, Hamburg, NORRIS Michael, THE SCRIPPS RESEARCH Germany - P133, P146, P147, P150 INSTITUTE, La Jolla, United States [email protected] [email protected]

MUÑOZ-MORENO Raquel, ICAHN SCHOOL OF OESTEREICH Lisa, BERNHARD NOCHT INSTITUTE MEDICINE AT MOUNT SINAI, New York, United FOR TROPICAL MEDICINE, Hamburg, Germany - States - 30, P228 P133, P146, P147, P150 [email protected] [email protected]

NAESENS Lieve, REGA INSTITUTE - KU LEUVEN, OHTA Keisuke, WAKAYAMA MEDICAL Leuven, Belgium - P014, P217 UNIVERSITY, Wakayama, Japan - P094, P095 [email protected] [email protected]

NAKANO Masahiro, JAPAN/KYOTO UNIVERSITY, OISHI Kohei, UNIVERSITY OF TOKYO, Minato-Ku, Kyoto, Japan - 45, P114 Japan - P035 [email protected] [email protected]

NAO Naganori, NATIONAL INSTITUTE OF OMAR Shadia, Newmarket, United Kingdom - INFECTIOUS DISEASES, Musashimurayama City, P134 Tokyo, Japan - P242 [email protected] [email protected] OUTLAW Victor, UNIVERSITY OF WISCONSIN– NEGRETE Oscar, SANDIA NATIONAL MADISON, Madison, United States - P175 LABORATORIES, Livermore, United States - P212 [email protected] [email protected] OYMANS Judith, WAGENINGEN BIOVETERINARY NG Weng, DIVISION OF STRUCTURAL BIOLOGY, RESEARCH, Utrecht, Netherlands - 57, 73 UNIVERSITY OF OXFORD, Oxford, United [email protected] Kingdom - P018 [email protected] PALACIOS Gustavo, USAMRIID, Frederick, United States - 63, P070, P174, P227 NIETO Amelia, CENTRO NACIONAL DE [email protected] BIOTECNOLOGIA-CSIC, Madrid, Spain - 33, 65 [email protected] PARIENTE Nonia, NATURE MICROBIOLOGY, PÖHLMANN Stefan, GERMAN PRIMATE CENTER, London, United Kingdom Göttingen, Germany - P065, P093, P196 [email protected] [email protected]

PARK Manseong, Seoul, Korea, Republic Of POROTTO Matteo, COLUMBIA UNIVERSITY [email protected] MEDICAL CENTER, Nw York, United States - 61, P175 PARKER Lauren, MEDIMMUNE/ASTRAZENECA, [email protected] Liverpool, United Kingdom - P187 [email protected] PORT Julia, BERHARD NOCHT INSTITUT, Hamburg, Germany - P133, P147 PARKINSON Nicholas, UNIVERSITY OF [email protected] EDINBURGH, Roslin, United Kingdom - [email protected] PRYCE Rhys, DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, PATTERSON Jean, San Antonio, United States - United Kingdom - P009, P018, P021 P012 [email protected] [email protected] PULIT-PENALOZA Joanna, CENTERS FOR DISEASE PENG Kah-Whye, MAYO CLINIC, Rochester, CONTROL AND PREVENTION, Atlanta, United United States - P031 States - P136 [email protected] [email protected]

PERNET Olivier, UCLA, Los Angeles, United PUNCH Emma, 1989, London, United Kingdom - States - P203 P022 [email protected] [email protected]

PFAFFINGER Verena, GENE CENTER - MAX VON RAMEIX-WELTI Marie-Anne, VERSAILLES SAINT PETTENKOFER-INSTITUTE OF VIROLOGY, QUENTIN UNIVERSITY, Montigny-Le- Munich, Germany - 27 Bretonneux, France - P027, P039, P213 [email protected] [email protected]

PFALLER Christian, MAYO CLINIC, Rochester, RANDALL Liz, UNIVERSITY OF ST ANDREWS, St United States - 2, 25, P067 Andrews, United Kingdom - 23 [email protected] [email protected]

PIETSCHMANN Thomas, TWINCORE, Hannover, RANDALL Richard, UNIVERSITY OF ST ANDREWS, Germany - 62, P020, P213 St Andrews, United Kingdom - 23, P072, P222 [email protected] [email protected]

PINTO Rute, THE ROSLIN INSTITUTE, THE RANJAN Punya, CENTRE FOR DISEASE CONTROL UNIVERSITY OF EDINBURGH, Edinburgh, United AND PREVENTION, Atlanta, United States - P210 Kingdom - P084 [email protected] [email protected] RASMUSSEN Angela, COLUMBIA UNIVERSITY, PLATTET Philippe, UNIVERSITY OF BERN, Bern, New York, United States - P128 Switzerland - P011, P122, P123 [email protected] [email protected] READING Patrick, PETER DOHERTY INSTITUTE ROGERS Kai, UNIVERSITY OF IOWA, Iowa City, FOR INFECTION AND IMMUNITY, Melbourne, United States - P079 Australia - 38 [email protected] [email protected] ROHDE Cornelius, INSTITUTE OF VIROLOGY, REGUERA Juan, INSERM, Marseille, France - 12, PHILIPPS-UNIVERSITY MARBURG, Marburg, P033 Germany - 31, P047 [email protected] [email protected]

RENNER Max, UNIVERSITY OF OXFORD, Oxford, ROSENTHAL Maria, BERNHARD NOCHT United Kingdom - P034, P048 INSTITUTE FOR TROPICAL MEDICINE, Hamburg, [email protected] Germany - P033 [email protected] RENNICK MURPHY Linda, BOSTON UNIVERSITY, Boston, United States - 55, P049, P153 ROTHENBERGER Sylvia, LAUSANNE UNIVERSITY [email protected] HOSPITAL, Lausanne, Switzerland - P007, P008, P182 REYNARD Stephanie, INSTITUT PASTEUR, Lyon, [email protected] France - P138, P181 [email protected] ROTTSTEGGE Monika, BERNHARD-NOCHT- INSTITUTE, Hamburg, Germany - P146 RICHARD Charles-Adrien, INRA, Jouy-En-Josas, [email protected] France - P027, P039, P051, P055 [email protected] ROUX Laurent, UNIVERSITY OF GENEVA, Geneva 4, Switzerland RICHARDSON Christopher, DALHOUSIE [email protected] UNIVERSITY, Halifax, Canada - P169 [email protected] ROUXEL Ronan, GSK, Rixensart, Belgium - P199 [email protected] RIMA Bert, QUEENS UNIVERSITY BELFAST, Belfast, United Kingdom - 61, P222 ROYMANS Dirk, JANSSEN PHARMACEUTICA NV, [email protected] Beerse, Belgium - 75, P200 [email protected] RINGEL Marc, PHILIPPS-UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany - RUBIN Steven, FDA, Silver Spring, United States - P110, P238 P153 [email protected] [email protected]

RISALVATO Jacquline, UNIVERSITY OF GEORGIA, RUIGROK Rob, IBS, Grenoble, France - 44, P026, Athens, United States - P043 P040 [email protected] [email protected]

RISSANEN Ilona, UNIVERSITY OF HELSINKI, RUSSELL Charles, ST. JUDE CHILDREN'S Helsinki, Finland - 10, P019, P248 RESEARCH HOSPITAL, MEMPHIS, TN, Memphis, [email protected] United States - 53 [email protected] SAKABE Saori, THE SCRIPPS RESEARCH SCHRAMM Antoine, AFMB CNRS, Marseille, INSTITUTE, La Jolla, United States - P088 France - P038, P058 [email protected] [email protected]

SATO Hiroki, INSTITUTE OF MEDICAL SCIENCE, SCHRAUF Sabrina, THEMIS BIOSCIENCE GMBH, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, Vienna, Austria P090, P096, P124, P137, P139 [email protected] [email protected] SCHULTZ-CHERRY Stacey, ST JUDE CHILDREN'S SCHAEFFER Justine, INSTITUT PASTEUR, Lyon, RESEARCH HOSPITAL, Memphis, United States - France - P138, P181 54 [email protected] [email protected]

SCHIERHORN Kristina, KING'S COLLEGE SCHULZ Helene, PUBLIC HEALTH AGENCY OF LONDON, London, United Kingdom - 39, P075 CANADA, Winnipeg, Canada - P232 [email protected] [email protected]

SCHLOTTAU Kore, FRIEDRICH-LOEFFLER- SCHULZE Jessica, ROBERT KOCH INSTITUTE, INSTITUT, Greifswald - Riems, Germany - P202 Berlin, Germany - 67 [email protected] [email protected]

SCHMALJOHN Connie, US ARMY MEDICAL SCHWEMMLE Martin, UNIVIVERSITY FREIBURG, RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Freiburg, Germany - 1, 19, 90, P196 Frederick, United States - P140, P161, P243 [email protected] [email protected] SELVARAJ Muneeswaran, THE PIRBRIGHT SCHMOLKE Mirco, UNIVERSITY OF GENEVA, INSTITUTE, Woking, United Kingdom - P158 Geneve, Switzerland - 36, P143, P206 [email protected] [email protected] SERNA MARTIN Itziar, UNIVERSITY OF OXFORD, SCHNEPF Daniel, MEDICAL CENTER UNIVERSITY Oxford, United Kingdom - 14, P034 OF FREIBURG, Freiburg Im Breisgau, Germany - [email protected] 56, P193 [email protected] SHCHERBIK Svetlana, CDC/NCRID, Atlanta, United States - P207 SCHOEPP Randal, USAMRIID, Fort Detrick, [email protected] United States - P223, P243 [email protected] SHI Xiaohong, UNIVERSITY OF GLASGOW, Glasgow, United Kingdom SCHOLTE Florine, CDC, Atlanta, United States - [email protected] 40, P131, P132 [email protected] SHU Bo, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P245, SCHOUNTZ Tony, COLORADO STATE P246 UNIVERSITY, Fort Collins, United States - 90, [email protected] P224 [email protected] SILVIA Ashley, TEXAS BIOMEDICAL RESEARCH STEEL John, EMORY UNIVERSITY, Atlanta, United INSTITUTE, San Antonio, United States - P054 States - 21, 89 [email protected] [email protected]

SLAINE Patrick, DALHOUSIE UNIVERSITY, STELFOX Alice, UNIVERSITY OF OXFORD, Oxford, Ridgeville, Canada - P155 United Kingdom - P218, P248 [email protected] [email protected]

SLOAN Elizabeth, CVR-UNIVERSITY OF STERTZ Silke, UNIVERSITY OF ZURICH, Zurich, GLASGOW, Glasgow, United Kingdom - 43, P032 Switzerland - 1 [email protected] [email protected]

SLOUGH Megan, ALBERT EINSTEIN COLLEGE OF STEVAERT Annelies, REGA INSTITUTE - KU MEDICINE, Bronx, United States - 6, P006 LEUVEN, Leuven, Belgium - P014, P217 [email protected] [email protected]

SOETENS Eline, VIB/UGENT, Anzegem, Belgium - STRECKER Thomas, Marburg, Germany - P118, P104 P159, P215 [email protected] [email protected]

SOLÀ RIERA Carles, KAROLINSKA INSTITUTET, SUBBARAO Kanta, THE PETER DOHERTY Stockholm, Sweden - 41 INSTITUTE FOR INFECTION AND IMMUNITY, [email protected] Melbourne, Australia - 76 [email protected] SONG Jin Won, KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of - P227 SUGAI Akihiro, THE UNIVERSITY OF TOKYO, [email protected] Tokyo, Japan - P053, P124, P137 [email protected] SPIROPOULOU Christina, Atlanta, United States - 40, P049, P131, P132, P172, P210 SUKHIASHVILI Roena, NATIONAL CENTER FOR [email protected] DISEASE CONTROL AND PUBLIC HEALTH (NCDC), Tbilisi, Georgia - P234, P243 SPRONKEN Monique, ERASMUS MEDICAL [email protected] CENTRE, Rotterdam, Netherlands - P041 [email protected] SZEMIEL Agnieszka, MRC - UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, STAEHELI Peter, UNIVERSITY OF FREIBURG, Glasgow, United Kingdom - P074 GERMANY, Freiburg, Germany - 56, P060, P193 [email protected] [email protected] TAHARA Maino, NATIONAL INSTITUTE OF STASS Robert, STRUBI, UNIVERSITY OF OXFORD, INFECTIOUS DISEASES, Musashimurayama, Oxford, United Kingdom - 10, P019 Japan - 92 [email protected] [email protected]

TAKADA Ayato, HOKKAIDO UNIVERSITY, Sapporo, Japan - P010, P184, P209, P240 [email protected] TAKAHASHI Hitoshi, NATIONAL INSTITUTE OF TENOEVER Benjamin, ICAHN SCHOOL OF INFECTIOUS DISEASES, Musashimurayama, MEDICINE, New York, United States - 30, 93, Japan - P177, P208 P078 [email protected] [email protected]

TAKAMATSU Yuki, INSTITUTE OF VIROLOGY, THAMAMONGODD Thiprampai, INSTITUTE OF PHILIPPS UNIVERSITY MARBURG, Marburg, VIROLOGY, MEDICAL CENTER UNIVERSITY Germany - P036 FREIBURG, Freiburg, Germany - 1, 19 [email protected] [email protected]

TAKASHITA Emi, NATIONAL INSTITUTE OF TILSTON-LUNEL Natasha, BOSTON UNIVERISTY, INFECTIOUS DISEASES, Tokyo, Japan - P177, Boston, United States - 55, P049 P180 [email protected] [email protected] TISCHLER Nicole, FUNDACIÓN CIENCIA PARA LA TAKEDA Makoto, NATIONAL INSTITUTE OF VIDA, Santiago, Chile - 6, 9, P007, P008, P149, INFECTIOUS DISEASES, Musashimurayama, P182 Japan - 92, P242 [email protected] [email protected] TOMONAGA Keizo, KYOTO UNIVERSITY, Kyoto, TAKIMOTO Toru, UNIVERSITY OF ROCHESTER Japan - 15, P044, P098, P105, P237 MEDICAL CENTER, Rochester, United States - [email protected] P063 [email protected] TONG Suxiang, CDC, Atlanta, United States - P235 TAKIZAWA Naoki, INSTITUTE OF MICROBIAL [email protected] CHEMISTRY (BIKAKEN), Tokyo, Japan - 51 [email protected] TORRIANI Giluia, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - 11, P007, TAMHANKAR Manasi Ajit, TEXAS BIOMEDICAL P008, P182 RESEARCH INSTITUTE, San Antonio, United [email protected] States - P012 [email protected] TOWNER Jonathan, Atlanta, United States - 63, P070 TE KAMP Verena, FRIEDRICH-LOEFFLER- [email protected] INSTITUT, Greifswald - Insel Riems, Germany - 49 TRIPATHI Shashank, ICAHN SCHOOL OF [email protected] MEDICINE AT MOUNT SINAI, New York, United States - P068, P069 TE VELTHUIS Aartjan, UNIVERSITY OF [email protected] CAMBRIDGE, Cambridge, United Kingdom - 66, 71 TSURUDOME Masato, CHUBU UNIVERSITY, [email protected] Kasugai, Japan - P002, P094 [email protected] TENG Michael, UNIVERSITY OF SOUTH FLORIDA, Tampa, United States - P170 [email protected] TYNELL Janne, KAROLINSKA INSTITUTET, VON RECUM Jessica, JANSSEN PHARMACEUTICA Stockholm, Sweden - P037 NV, Beerse, Belgium [email protected] [email protected]

UCHIDA Shotaro, JAPAN, Tokyo, Japan - P090, WALKER Alex, UNIVERSITY OF OXFORD, P139, P211 Cirencester, United Kingdom - P056 [email protected] [email protected]

UEKI Hiroshi, INSTITUTE OF MEDICAL SCIENCE, WARREN Travis, US ARMY MEDICAL RESEARCH UNIVERSITY OF TOKYO, Tokyo, Japan - 68 INSTITUTE OF INFECTIOUS DISEASES, Frederick, [email protected] United States - 70 [email protected] ULRICH Rainer, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald-Insel Riems, Germany - P236 WATANABE Yasunori, UNIVERSITY OF [email protected] SOUTHAMPTON, Oxford, United Kingdom - P215, P218 URATA Shuzo, NAGASAKI UNIVERSITY, [email protected] INSTITUTE OF TROPICAL MEDICINE, Nagasaki, Japan - 72, P118 WATANABE Yohei, KYOTO PREFECTURAL [email protected] UNIVERSITY OF MEDICINE, Kyoto, Japan - P226, P244 VAN KNIPPENBERG Ingeborg, UNIVERSITY OF [email protected] GLASGOW, Glasgow, United Kingdom - P032 [email protected] WATKINSON Ruth, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - VERA OTAROLA Jorge, LABORATORIO DE P203 VIROLOGÍA MOLECULAR, INSTITUTO MILENIO [email protected] DE INMUNOLOGÍA E INMUNOTERAPIA, CENTRO DE INVESTIGACIONES MÉDICAS, WEARY Taylor, TEXAS BIOMEDICAL RESEARCH DEPARTAMENTO DE ENFERMEDADES INSTITUTE, San Antonio, United States - 59 INFECCIOSAS E INMUNOLOGÍA PEDIÁTRICA , [email protected] ESCUELA DE MEDICINA, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE., Santiago, WEBER Friedemann, JUSTUS LIEBIG UNIVERSITY Chile - P100 GIESSEN, INSTITUTE FOR VIROLOGY FB10, [email protected] Giessen, Germany - P083, P089, P103 [email protected] VOLCHKOV Viktor, CIRI INSERM 1111, Lyon, France - P097 WELCH Stephen, CENTERS FOR DISEASE [email protected] CONTROL AND PREVENTION, Atlanta, United States - 40, P049, P132, P172 VOLCHKOVA Valentina, CIRI 1111, Lyon, France - [email protected] P097 [email protected] WENTWORTH David, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United VON MESSLING Veronika, PAUL-EHRLICH- States - 80, P164, P207, P245, P246 INSTITUT, Langen, Germany - 69 [email protected] [email protected] WHELAN Sean, HARVARD MEDICAL SCHOOL, YANAI Mako, KYOTO UNIVERSITY, Kyoto, Japan - Boston, United States - 13, 24, P016, P050, P179 P044, P105 [email protected] [email protected]

WICHGERS SCHREUR Paul, WAGENINGEN YANG Patrick (Genyan), CDC, Atlanta, United BIOVETERINARY RESEARCH, Lelystad, States Netherlands - 57, 73 [email protected] [email protected] YASUDA Jiro, NAGASAKI UNIVERSITY, Nagasaki, WIECHERT Svenja, TWINCORE, CENTRE FOR Japan - 72, P077, P118, P247 EXPERIMENTAL AND CLINICAL INFECTION [email protected] RESEARCH, Hannover, Germany - P020, P213 [email protected] YASUHARA Atsuhiro, INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, JAPAN, Tokyo, WIGNALL-FLEMING Elizabeth, UNIVERSITY OF ST Japan - 77, P135 ANDREWS, St Andrews, Fife, United Kingdom - [email protected] 23, P222 [email protected] YE Liang, INSTITUTE OF VIROLOGY, MEDICAL CENTER UNIVERSITY OF FREIBURG, Freiburg, WILLIAMS Evan, UNIVERSITY OF TENNESSEE Germany - 56, P193 HEALTH SCIENCE CENTER, Memphis, United [email protected] States - P085 [email protected] YILDIZ Soner, UNIVERSITY OF GENEVA, CMU, Geneva, Switzerland - P143 WU Kai-Hui, CENTERS FOR DISEASE CONTROL [email protected] AND PREVENTION, Atlanta, United States - P245, P246 YONEDA Misako, THE UNIVERSITY OF TOKYO, [email protected] Tokyo, Japan - P053, P090, P096, P124, P137, P139, P211 WUERTH Jennifer, JUSTUS-LIEBIG UNIVERSITY [email protected] GIESSEN, Giessen, Germany - P083 [email protected] YOSHIDA Asuka, THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, XUE Miaoge, THE OHIO STATE UNIVERSITY, Japan - P090, P120 Columbus, United States - 16, P195, P216 [email protected] [email protected] YOSHIDA Reiko, HOKKAIDO UNIVERSITY, YAHIRO Mukai, INSTITUTE FOR FRONTIER LIFE Sapporo, Japan - P010, P209 AND MEDICAL SCIENCES , KYOTO UNIVERSITY, [email protected] Kyoto, Japan - 87 [email protected] YOSHIKAWA Rokusuke, NAGASAKI UNIVERSITY, Nagasaki-Shi, Japan - P077 YAMAYOSHI Seiya, INSTITUTE OF MEDICAL [email protected] SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan - 77, P035, P135 ZAECK Luca, FRIEDRICH-LOEFFLER-INSTITUT, [email protected] Greifswald - Insel Riems, Germany - 49, P156 [email protected] ZAHN Roland, JANSSEN VACCINES & PREVENTION, Leiden, Netherlands - P189 [email protected]

ZHOU Yan, UNIVERSITY OF SASKATCHEWAN, Saskatoon, Canada - P062 [email protected]

ZIEGLER Christopher, UNIVERSITY OF VERMONT, Burlington, United States - 47, 48, P112 [email protected]

ZIMMER Gert, INSTITUTE OF VIROLOGY AND IMMUNOLOGY (IVI), Mittelhäusern, Switzerland - 11, P005, P007, P008, P182, P231 [email protected]

ZUEST Roland, SPIEZ LABORATORY, Spiez, Switzerland - [email protected] to do list … to be continued …

… see you all again for #NSV2021 …

where would you go …?

www.negativestrandvirus.org [email protected]

Back cover image courtesy of Seema Lakdawala, University of Pittsburgh, USA